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     Targeted detection of bio-molecules in vivo and in the environment is a key area of 
research. Surface enhanced Raman spectroscopy (SERS) is emerging as a non-
invasive platform for detection of a large variety of biomolecules. Here, bio-
nanotechnology was investigated to further enhance the capabilities of SERS as a bio-
sensor platform. Specifically, a system was developed using oligonucleotide labeled 
nanoparticles for multiplex detection of small nucleotide polymorphisms in the K-Ras 
oncogene at a 10 pM detection limit. The binding kinetics and fluorescence quenching 
of CTAB coated gold nanorods were also investigated for use in detection of 
hydrophobic biomolecules. Fluorescence quenching of Nile Red and IR-786 was 
found to be independent of binding affinity, as determined by surface plasmon 
resonance. A novel method of functionalizing proteins to nanoparticles was developed 
for use in SERS and other nanoparticles based platforms. The system uses 
selenocysteine mediated cleavage of a protein splicing element known as an intein. 
The selenocysteine activated protein can then be functionalized to any selenocysteine 
reactive surface or functional group in a pH dependent manner. After development 
using a maltose binding protein model, fluorescein labeling of an intein tagged single 
chain antibody against the A33 cancer antigen was confirmed by florescence activated 
cell sorting.   
 
 iii 
BIOGRAPHICAL SKETCH 
     
     Adam Joseph Lowe was born on February 12
th
, 1985 in Salisbury, MD to Wayne 
Wingate Lowe and Susan Harshman Lowe. He grew up on the Eastern Shore of 
Maryland, nestled between the Chesapeake Bay and the Atlantic Ocean. Adam 
attended Salisbury Christian School from kindergarten through 12
th
 grade, graduating 
valedictorian and received the Joshua Leadership Award. He went on to graduate from 
Salisbury University Summa Cum Laude in December 2006, completing his Bachelors 
of Science in Biology in three and a half years. While at SU, Adam was awarded the 
Wallace Q. French Memorial Environmental Scholarship, was inducted into the Phi 
Kappa Phi Honor Society, participated in the NSF REU program at Cold Spring 
Harbor Labs, and won the Biology Faculty Award.  
     Adam began his PhD in Microbiology from Cornell University in the fall of 2007 
after being admitted as a Presidential Life Sciences Fellow. After three rotations, he 
chose to work for Prof. Carl Batt on applied biotechnology. In addition to his research, 
Adam worked in the Ludwig Institute for Cancer Research Bio-Production Facility. 
There he helped produce the cancer vaccines SM-14, NY-ESO-1, and Melan-A. Adam 
also worked with the Johnson school as the Chair of the Technology Advisory Board 
for the Big Red Venture Capital Fund. While in Ithaca, Adam enjoyed his friends, the 
occasional warm days Ithaca provides, and the Chapter House. Upon graduation, 
Adam was hired as a Principal Research Scientist for SRC Inc. in Syracuse, NY.   
 iv 
 
 
 
 
 
 
 
 
 
 
 
To my parents, who gave me the foundation upon which I have built everything.
 v 
ACKNOWLEDGMENTS 
 
     I would like to gratefully acknowledge Prof. Carl Batt for allowing me to work in 
his lab and for his mentorship during my tenure as a graduate student. While I learned 
many academic lessons as Cornell, I think the sage advice Carl gave me about life and 
how science really works will stick with me for much longer. I would also like to 
acknowledge my minor advisors Prof. Linda Nicholson and Prof. Matt DeLisa for 
always being willing to talk about science and open to bounce ideas off of. It is also 
important that I acknowledge Dr. Aaron Strickland for his help and friendship while 
he was with the lab.  
     I want to thank the Ludwig team of Cameron, Kyle, Jack, Rishard, Deuce, and Leo 
D. I really enjoyed the camaraderie and learned a lot from you all. A special 
acknowledgement goes to Cameron who worked shifts with me for 48 hours straight 
to get through Melan-A production.  
     Finally, I would like to acknowledge my friends and family who helped me get 
through what was sometimes a bumpy road. Specifically, I want to acknowledge my 
fiancée Nicholle for her never-ending love and support, even when it meant waking 
her up at 3 AM so I could go back to the facility.  I also want to acknowledge Jennifer 
Nelson, Brian Forster, and Eric Strobel for always being willing to listen about another 
failed experiment or my latest and greatest idea. 
 vi 
TABLE OF CONTENTS
 
Biographical Sketch……………………………………………………………  iii 
Dedication………………………………………………………………………. iv 
Acknowledgements……………………………………………………………... v 
Chapter 1………………………………………………………………………... 1     
Chapter 2……………………………………………………………………….. 40 
Chapter 3……………………………………………………………………….. 59 
Chapter 4……………………………………………………………………….. 84 
Chapter 5………………………………………………………………………. 111 
Appendix I……………………………………………………………………... 115 
Appendix II…………………………………………………………………...... 142 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
1 
 
CHAPTER 1 
DESIGNING FUNCTIONALIZED METALLIC NANOMATERIALS FOR 
SENSING BIO-MOLECULES BY SURFACE ENHANCED RAMAN 
SPECTROSCOPY 
  
 2 
Abstract 
 
This brief literature review addresses the key points of consideration when designing a 
surface enhanced Raman spectroscopy (SERS) based system for sensing bio-
molecules. It begins by briefly explaining the history of Raman spectroscopy and the 
mechanisms behind the surface enhancement effect. Within this section, the review 
also addresses the excitation wavelength and distance dependence of SERS. It also 
discusses surface enhanced resonance Raman spectroscopy (SERRS), and tip 
enhanced Raman spectroscopy (TERS) as specialized SERS platforms. The review 
then analyzes Raman enhancer and surface functionalization choices as key design 
elements. Finally, the review concludes with previous applications of SERS, 
demonstrating its ability to function as a bioanalytical tool in a variety of roles. 
 3 
Introduction & Essential SERS Principles    
 
Raman Spectroscopy is the study of inelastic scattering of light, where a molecule is 
excited to a virtual state, then relaxes to a vibrational state slightly higher or lower in 
energy than its original ground state.   This phenomena was first observed in the late 
1920s
(1)
 by Sir C.V. Raman for whom the field gained its namesake. Surface enhanced 
Raman spectroscopy (SERS) was accidentally discovered in 1974
(2)
 when a group was 
studying pyridine absorbed onto a roughened silver substrate. The large amplification 
in Raman signal could not be accounted for by an increased number of molecules due 
to the larger surface area after surface roughening. From there, subsequent studies 
began to understand how nanostructured metals could enhance Raman signals, and 
realized the significance of SERS as an analytical tool. 
 
Recent studies have revealed a two-part mechanism contributes to SERS 
enhancement.
(3-7)
 First, SERS enhancers contribute to signal amplification 
electronically. An energy source excites the electron clouds of colloidal metals or 
other nanostructures, inducing a localized field of energy called a plasmon. Figure 1-
1A shows the electric field and shift in the electron cloud that is propagated across two 
excited nanoparticles. Figure 1-1B diagrams the extinction efficiency of the field, 
plotting the ratio of particle cross section against the effective area of the field for a 35 
nm Ag nanoparticle. |E|
2
 denotes the absolute enhancement field intensity. The reason 
this shift occurs is the polarizability of the nanoparticles, which cannot occur in bulk 
materials.
(8-10) 
The polarizability in turn comes from the incredibly high surface to area 
ratio and small size of nanostructures.
(11)
 This “quantum” size effect occurs when   
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Figure 1-1 (a) Illustration of the localized surface plasmon resonance effect. (b) 
Extinction efficiency (ratio of cross section to effective area) of a spherical silver 
nanoparticle of 35-nm radius in vacuum. |E|
2
 (absolute field enhancement) 
contours are shown for a wavelength corresponding to the plasmon extinction 
maximum, illustrating the strong distance dependence of enhancement. Peak |E|
2
 
= 85.  
 
 
(Annual review of analytical chemistry Copyright 2008 by ANNUAL REVIEWS, INC.. Reproduced with 
permission of ANNUAL REVIEWS, INC. in the format Dissertation via Copyright Clearance Center.)   
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a gap forms between the valence electrons and the conducting  electrons in the metal, 
which cannot occur in bulk form of the metal.
(12)
 While theoretical and experimental 
evidence has shown that the electronic effect is the dominant contributor to SERS 
enhancement
(13-15)
, a chemical enhancement
(16)
 also occurs which is multiplicative
(13)
 
with the electronic enhancement. Chemical enhancement works by allowing charge 
transfer through the metallic surface to go from the highest occupied molecular orbital 
(HOMO) to the lowest unoccupied molecular orbital (LUMO) of the absorbed 
molecule, costing only half the energy required to go directly from the HOMO to 
LUMO energy levels.
(13, 17)
 More recently, this has been further confirmed by detailed 
study of charge transfer of substituted pyridine rings, which found that chemical 
enhancement was mainly governed by the distance between HOMO and LUMO 
orbitals, and not the dipole moments induced by charge transfer from the pyridine ring 
to its substituted groups.
(16) 
  
 
It is important to note that the enhancement effects described here are dependent on 
distance and excitation wavelength.
(18)
 It has been empirically determined that SERS 
enhancement is 10
th
 power dependent on distance from the enhancing field of the 
metal, thus SERS enhancement greatly drops as the absorbate moves away from the 
metal.
(19, 20)
 Practically, this is also very important when trying to get a clear Raman 
signal using a fluorescent Raman reporter. While fluorophores often make excellent 
Raman reporters due to their high Raman active cross-sections, if they are not properly 
quenched, the fluorescence can overpower the Raman signal. In close proximity 
metals such as gold and silver can quench fluorescence,
(12, 17, 21-26)
 while at 
intermediate distances, metal can actually enhance fluorescence.
(27-30)
 The exact 
distances depend on both the fluorophore and the substrate. Consideration of these 
effects is key however when designing a SERS biosensing system that uses 
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fluorophore labeled detection. A typical setup for a SERS biosensor can be seen in 
Figure 1-2. Antibodies capture the biological target of interest onto a surface. The 
basal substrate (shown in gold) can then act as an enhancer or affinity labeled tags 
(silver spheres) can be added to provide SERS enhancement. These same tags can be 
labeled with Raman active substrates to provide a diagnostic signal if the intrinsic 
Raman signal of the biological target is too weak. 
 
Excitation wavelength is also an important factor when designing a SERS biosensor 
because it may directly affect the degree of signal enhancement.
(31, 32)
 A wavelength 
must be chosen that maximizes localized surface plasmon resonance absorbance while 
minimizing absorbance of the bulk metal. Since most Raman spectrophotometers have 
limited excitation wavelength choices, a general rule is that silver provides better 
Raman scattering at shorter wavelengths (485 nm- 532 nm) while gold provides better 
scattering in at longer wavelengths such as 785 nm. Aggregated colloids and 
engineered nanostructures with multiple or broad plasmon bands can often ignore 
excitation wavelength considerations as they provide excellent scattering across a 
range of excitation wavelengths.
(33)
 Additionally, when the excitation wavelength 
induces an electronic transition in the analyte, its chemical enhancement of Raman 
scattering is often more significant than optimizing the localized surface plasmon 
resonance (LSPR) of the Raman enhancing substrate. This phenomena is known as 
surface enhanced resonance Raman spectroscopy (SERRS) and can often provide 
much larger signal enhancement than traditional SERS.
(34, 35)
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Figure 1-2 Typical setup for SERS biosensors. Antibodies or affinity elements 
bind the biological target of interest and labeled SERS tags act as enhancers and 
produce diagnostic spectra.  
 
Taken from http://spie.org/Images/Graphics/Newsroom/Imported-
2011/003645/003645_10_fig2.jpg. Accessed 7/14/2011. 
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SERS Platforms  
 
Since the early 2000s, advances in the production of nanomaterials and progress in 
understanding their electronic properties has greatly broadened the use of SERS as an 
analytical tool. It has also broadened the variety of SERS based platforms used to do 
this analysis. Specialized forms of SERS such as SERRS, TERS, and solution SERS 
provide alternatives to metallic substrate based methods that may be better suited to 
specific analytic problems.   
 
SERRS is an important type of SERS that is often used as an analytic technique 
without being specifically described as such. SERRS occurs when the excitation 
source matches the absorbance of the analyte bound to the Raman enhancer. SERRS 
may be used with a variety of enhancers such as solution SERS, roughened substrates, 
colloidal metals or engineered nanostructures. SERRS lends itself to DNA 
oligonucleotide based sensing systems
(36-42)
, as fluorophore labeled probes are readily 
available and often match existing excitation wavelengths. SERRS is particularly 
sensitive to matching the excitation source with the absorbance wavelengths of the 
analyte, but it does not have to be a perfect match, as there will still be some 
absorbance “off-peak”. Resonant Raman spectroscopy is even possible if the 
excitation wavelength does not match at all through Resonance Hyper-Raman 
Spectroscopy.
(43)
 This setup requires two-photon excitation however and is a relatively 
“niche” mode of spectroscopy.  
 
Tip-enhanced Raman spectroscopy (TERS)
(44)
 is another unique version of SERS that 
is particularly useful for surface characterization and probing.
(45-48)
 Figure 1-3 shows a 
diagram of a typical TERS setup. An atomic force microscopy (AFM) tip is coated  
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Figure 1-3 Schematic of the experimental arrangement for TERS. The incident 
light is focused onto the tip–sample gap. The tip enhanced and -scattered 
Raman response is spectrally filtered using a notch filter and is spectrally 
resolved by an imaging spectrometer with a liquid nitrogen-cooled charge-
coupled device array, or integrally detected by means of an avalanche 
photodiode (APD). Polarization directions of both incident and scattered light 
beams can be controlled independently. The blue layer indicates a thin water 
film as may be present on the sample under ambient conditions. Reprinted with 
permission.  Springer Press. 2009.  
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with gold or a metallic nanoparticle is attached to the tip, then the tip is passed over 
the surface to be analyzed under laser excitation. This is particularly useful for probing 
bio-functionalized surfaces
(49)
 or detecting functional groups on a cell or membrane 
surface.
(50, 51) 
TERS also confers another degree of data because the AFM tip can still 
be used to gather AF data, providing even more information about the surface. A 
drawback of TERS is that it is still an emerging field, and does require some special 
equipment beyond a normal setup. More commercially available “turnkey” setups are 
emerging on the market, making them accessible to individuals uninterested in 
building one from scratch. 
 
 Particle Types & Properties 
 
After choosing the most appropriate form of SERS and noting the excitation 
wavelengths available, the next most important decision is the choice of Raman 
enhancer. This choice, in conjunction with excitation wavelength, dictates the degree 
of Raman enhancement achievable. It also dictates the routes through which the 
enhancer can be functionalized and in which environment the metallic enhancer will 
be stable. While there is an abundance of interesting nanofabricated substrates for 
SERS
(31, 33, 52-54)
, this review will focus on the discussion of metallic nanoparticles. 
Particles are often more suited for analysis of biological systems due to their ability to 
be added to solution, and often have more flexibility than substrate based systems. 
 
Metallic Colloids   
 
While there is no “optimal” Raman enhancer, gold and silver have become the field 
standards. These metals are popular due their high plasmon induction to surface area 
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ratio, wide availability, and thiol chemistry compatibility. Other metals such as Al, Li, 
Cu and Cd are Raman active but have not become popular due to lower overall Raman 
enhancement and difficulty to work with.
(7, 55-57) 
The choice between silver and gold 
depends on the assay desired. For a given size of spherical nanoparticle, silver offers 
higher signal enhancement
(58) 
and provides optimal enhancement when excited in the 
UV and short wavelength visible light bands. This matches well with assays using 
DNA functionalized nanoparticles which often utilize fluorophores that absorb in the 
same range as silver, enabling SERRS enhancement.
(58-64)
 Silver is much more prone 
to precipitation than gold however, and must be fully passivated prior to exposure to 
biological samples or samples containing even modest salt concentrations. It should be 
noted that controlled aggegation of particles can be highly beneficial. Inter-particle 
enhancement can create “hot-spots” that greatly enhance overall Raman signal.(65-67) 
Silver is also not nearly as biocompatible as gold. Colloidal silver is highly 
microbicidal
(68-71)
 and has been shown to cause morphology changes in mammalian 
cells.
(72)
 In addition to being biocompatible, gold is also a good choice for Raman 
detection within tissues, as it can be excited in the near-IR range where tissue does not 
absorb light.
(73-75)
  
 
Size and shape are the other two contributing factors when choosing a colloidal 
Raman enhancer. Generally speaking, a larger particle is better when choosing a 
nanoparticle due to a larger outer surface area for the LSPR to couple through.
(76-79) 
This is limited however, up to a maximum of about 200 nm
(78) 
due to signal 
dampening from the „bulk‟ metal. It is important to note however that the particle must 
still be matched with excitation wavelength as previously discussed to maintain 
optimum signal enhancement. Choice of nanoparticle shape is a much more complex 
issue.
(52, 80-82) 
Spheres are advantageous because they are the best-studied variety, are  
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easy to synthesize, and are commercially available if desired. They may also be 
dimerized in a controllable fashion to create Raman active hotspots for increased 
signal enhancement as seen in Figure 1-4.
(83)
 Figure 1-4a illustrates the hot-spot 
interaction between two spheres and Figure 1-4b shows how an array of spherical 
dimers can be incorporated into a silica wafer.  
 
Non-spherical metallic nanoparticles have also been extensively analyzed
(82)
 and have 
demonstrated SERS enhancing properties for bio-detection
(84-86)
. Detailed calculations 
have been done on nanowires featuring irregular cross sections, calculating SERS 
enhancement up to 10
12
 under ideal conditions, which makes them very desirable 
SERS enhancers. Non-spherical nanoparticles are particularly interesting for SERS 
because the LSPR(s) of the particle are not evenly distributed. Edges on the particle 
are thinner and thus give rise to unique plasmonic fields. By changing the shapes and 
aspect ratios, it is possible to tune the LSPR(s) of the particles and thus change the 
enhancer to a detection system‟s needs. This can be very advantageous when working 
within biological constraints. Several groups have also been able to magnetize 
spherical
(87) 
and non-spherical particles
(88-90)
 by creating noble metal-iron oxide 
hybrids. The magnetization of the particle is a great advantage as the particle can be 
manipulated across a cell or membrane surface or be used to aggregate particles for 
high signal localization. The major drawback to non-spherical metallic nanoparticles is 
a more complex synthesis. Careful control of synthetic parameters is required to obtain 
monodispersed particles in the shape desired. Methods of synthesis include 
photoinduction, wet chemical reduction, and lithography and have been well 
reviewed.
(91)
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(a) 
Figure 1-4 a) Diagram of two spherical nanoparticles interacting to create a 
Raman active hot spot. Note the distance of less than 5 nm required between 
the particles for the effect to occur. b) Gold dimer array fabricated 
by a combination of pattern replication, wafer processing techniques, and 
solvent evaporation. This repeated array creates a homogenous, Raman 
enhancing substrate for analysis. Reprinted with permission.  John Wiley & 
Sons Ltd. 2009. 
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CTAB Functionalized Gold Nanorods 
 
Cetyltrimethylammonium bromide (CTAB) functionalized nanorods are a unique 
variety of nanoparticle that deserve special mention for SERS bio-detection. They are 
interesting because their aspect ratio is tunable and they can be selectively 
functionalized in a number of ways. The nanorods may be tuned by changing the 
aspect ratio of the particles, which in turn directly affects their transverse and 
longitudinal LSPR peaks. The location of these plasmons is critical for SERS 
enhancement, as Raman intensity has been shown to be a direct function of the aspect 
ratio.
(92) 
These rods are also interesting because they may be preferentially 
functionalized on their terminal ends rather than on the sides.
(93) 
This phenomenon is 
due to lack of CTAB on the (111) terminal faces because the (100) side faces allow for 
proper CTAB head group packing.
(94)
 This allows a variety of bio-molecules such as 
oligonucleotides or antibodies to be selectively conjugated to the particle while 
maintaining the CTAB coating. The CTAB coating is a non-polar environment but has 
been able to detect non-polar small molecules by SERS
(95) 
and has served as a carrier 
for florescent molecules which can be used as SERS reporters.
(96)
 The CTAB may also 
be exchanged off completely once the particles are synthesized for subsequent 
functionalization with affinity groups and SERS interrogation of the bio-analyte of 
interest.
(97-99) 
Overall, CTAB coated nanorods are a very good choice for Raman 
enhancer, but do require a moderately difficult synthesis for a monodispersed yield. 
The hydrophobicity of the CTAB bilayer may also not be compatible with some buffer 
systems or target molecules.  
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Functionalization for Molecular Recognition & Stability 
 
While a molecule can be absorbed directly onto a Raman enhancer, most SERS based 
bio-detection systems will require functionalization of the enhancer with a moiety that 
has affinity and specificity for the target molecule. The choice of Raman enhancer 
often dictates how the particle will be functionalized to bind the target bio-molecule. 
Silver and gold nanoparticles are compatible with thiol chemistry for direct linkage of 
the capture probe to the particle. The coordination chemistry of the thiol bond to gold 
nanoparticles has been extensively researched
(100)
 revealing a strong and stable bond 
system. Thiol bonds are often utilized in systems with oligonucleotide capture probes 
or aptamers, where the DNA is terminally thiolated and directly attached to the 
particles.
(101-105)
 Oligonucleotide aptamers are particularly interesting because they can 
bind a large variety of molecule types in a manner similar to antibodies, though 
typically with less affinity.
(106-109)
 These systems are well studied, and extensive 
progress has been made to optimize DNA loading
(110-112) 
and particle stability
(113)
. 
Antibodies or other protein based affinity probes can also be directly conjugated to 
nanoparticle surfaces through the thiol of cysteine groups. It has been demonstrated 
that using naturally occurring and engineered cysteines for attachment can greatly alter 
protein function depending upon cysteine placement, with terminal cysteines causing 
the least alteration of function.
(114)
  
 
Metallic nanoparticles can also be functionalized with linker groups such as amines, 
thiols, aldehydes, or alkynes. These groups are typically incorporated by encapsulating 
an uncapped particle with PEG containing the desired functional group at its solvent 
exposed terminus. Before using a long chain PEG or undertaking this approach it 
should be noted that Raman enhancement will be less than direct attachment to the 
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particle due to a longer distance from the target molecule to the metal enhancer. The 
most common method for linking proteins and other carboxyl or amine bearing 
molecules is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)-N-
Hydroxysuccinimide (NHS) chemistry where the carboxyl group is made amine 
reactive by preparation with EDC then NHS.
(115, 116)
 This methodology is fairly non-
specific however and some loss of function occurs due to functionalization through 
critical amine or carboxy R groups in the protein. Cysteines in the protein can be used 
to conjugate to maleimide functionalized PEG but have the same loss of function 
problem as previously mentioned for direct attachment. “Click chemistry” is also a 
popular alternative but has some implementation problems. The method requires a 
reaction between an alkyne and an azide, severely limiting the types of biomolecules 
that can be attached without further use of “adapter” molecules.(117)  
 
An alternative method to put proteins on particles involves using an engineered intein. 
An intein is a self-splicing protein element that behaves similarly to exons and introns 
in RNA. The intein post-translationally splices itself out of the protein in a multistep 
transesterification-succinimide release process that also splices the two remaining 
domains of the proteins, known as exteins, together.
(118)
 Several approaches have been 
used to attach proteins to nanoparticles via inteins. Some have used split inteins
(119)
 
while most other groups have used intein mediated protein ligation (IPL) to put 
proteins on particles. In IPL, a thiol containing compound such as MESNA is used to 
induce intein cleavage then the protein may be ligated to any thiol reactive group. A 
modified form of IPL has even been combined with click chemistry to achieve site 
specific conjugation.
(120)
 Recently, some work has been done with inteins and 
recombinant engineering to incorporate selenocysteine (Sec) into proteins for 
attachment and reactivity.
(121-123) 
Selenocysteine is reactive with the same groups as 
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thiols but is more nucleophilic
(124, 125)
 and forms a more stable bond with gold.
(126) 
Sec 
is especially interesting due to its low pKa; it is still reactive at lower pH values where 
cysteine has been protonanted. This means Sec can be used as a site-specific 
functionalizing agent in a pH dependent manner.  
 
Non-covalent physical interactions may also be used to target bio-molecules for 
Raman enhancement. This is especially useful when trying to detect a class of 
molecules similar to each other. In addition to the examples previously discussed, the 
CTAB bilayer around of coated particles has been used in a variety of ways as a 
delivery vehicle and could be used in a similar manner to hold a capture group.
(127-129)
 
Protein absorption onto nanoparticles through non-covalent interactions, particularly 
through non-covalent affinity schemes has been extensively reviewed.
(130)
  The 
strongest non-covalent bond used for labeling is the biotin-streptavadin interaction 
which has been extensively used to label particles for SERS.
(102, 131-133) 
The drawback 
to this approach however, is that both the target and the enhancer need to be labeled 
which is not possible in many sensing schemes. This approach is more appropriate for 
easy labeling of reporter dyes to the nanoparticle if the target itself does not provide 
enough Raman signal.  
 
Bio-Sensing Applications  
It is beyond the scope of this review to analyze all the applications of SERS 
biosensors, but a few interesting uses stand out. SERS biosensors often use DNA as a 
capture probe for their target. While many have detected small molecules or specific 
sequences, only a few have interrogated small nucleotide polymophisms (SNPs).
(64, 134-
136)
 SNPs are an important research topic because these single mutations are the most 
common variations across a genome and can be used to directly detect alleles 
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responsible for a trait of interest.
(137, 138)
 Lowe et. al, for example, was able to show 
multiplex detection of three cancer haplotypes and correlate Raman intensity to DNA 
copy number.
(135)
 In addition to DNA targets, small molecules also make up a large 
portion of SERS based bio-sensor targets. While many DNA and protein capture 
probes are often used, synthetic oligosaccharides have also been used to specifically 
capture pesticides.
(139)
 At the cellular level, SERS has been able to identify microbial 
species, manipulate microbial cells via optical Raman tweezer, and determine their 
spatial distribution in vivo.
(140)
  Researchers have also been able to use SERS for 
“imaging” of tumors and other mammalian cell system, differentiating cells types 
based on their Raman spectra.
(141, 142) 
SERS biosensors have also been actively used in 
environmental studies. This has been described in an excellent review, citing examples 
of detection of pollutants in air, water and soil as well as analysis of living tissue from 
the environment.
(143)
 While almost all the studies previously mentioned have used 
SERS detectors as close to the sample as possible, stand-off SERS is also possible.
(144) 
In this setup, the target can be meters away from the detector and excitation source, 
but the enhancing element must still be adjacent to the particle. 
 
This is particularly 
useful for detection of harmful chemical reagents or explosive components.  
 
Concluding Thoughts  
 
 
This dissertation research directly addresses several important questions in the field of 
SERS biosensors. The second chapter examines whether it is possible to detect SNPs 
using SERS and if so, if it could be done in a multiplex fashion. Building upon that 
work, the third chapter examines CTAB coated nanoparticles, which have been used 
as SERS enhancers. It specifically addresses how non-polar dyes traffick through the 
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CTAB bilayer and how the molecules’ affinity affects FRET. Quenching of 
fluorescence is critically important to obtain a clear Raman spectrum. Finally, the 
fourth chapter addresses nanoparticle functionalization for use in SERS and other bio-
nanotechnology platforms. The system developed demonstrates an amino acid 
specific, pH selective method for conjugating proteins to nanoparticles. This increases 
efficiency as compared to non-specific methods such as EDC-NHS chemistry, which 
can interrupt critical, structural amino acids on the proteins’ surface.
 20 
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MULTIPLEX SNP GENOTYPING UTILIZING LIGASE DETECTION REACTION 
COUPLED SERS 
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Abstract:      
Single nucleotide polymorphisms (SNPs) are one of the key diagnostic markers for 
genetic disease, cancer progression, and pharmcogenomics.  The ligase detection 
reaction (LDR) is an excellent method to identify SNPs, combining low detection 
limits and high specificity.  We present the first multiplex LDR-Surface Enhanced 
Raman Spectroscopy (SERS) SNP genotyping scheme.  The platform has the 
advantage in that the diagnostic peaks of Raman are more distinct than fluorescence 
and, in theory, a clinically significant number of markers can be multiplexed in a 
single sample using different SERS reporters.  Here we report LDR-SERS multiplex 
SNP genotyping of K-Ras oncogene alleles at 10 pM detection levels, optimization of 
DNA labeling as well as Raman conditions, and the linear correlation of diagnostic 
peak intensity to SNP target concentration in heterozygous samples.  Genomic DNA 
from typed cells lines was obtained and scored for the K-Ras genotype.  These 
advances are significant as we have further developed our new SNP genotyping 
platform and have demonstrated the ability to correlate genotype ratios directly 
diagnostic Raman peak signal intensity.  
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Introduction:    
     SNPs are clinically useful for disease diagnosis and the selection of the appropriate 
therapies.
1-3
 The ability to genotype multiple SNPs in limited clinical samples is 
important due to their potential for heterogeneous distribution.  For example, 
oncogenic K-Ras alleles have been detected at G12V, G12A, G13D, and Q61R.
4
 The 
K-Ras genotype from a patient’s tumor is highly informative, as tumors with different 
genotypes respond differently to treatment regiments.
5-7
 Many methodologies have 
been previously developed for SNP genotyping.  Strategies include primer elongation 
via PCR, enzymatic cleavage, hybridization, and LDR (oligonucelotide ligation), with 
most of them relying on a fluorescent spectra or mass spectrometry for signal output.
8
 
Fluorescence is limited as a multiplex reporter due to spectral overlap.  Mass 
spectroscopy is able to deconvolute more complex mixtures since different mass tags 
can be used
9,10
, but the equipment is cumbersome and difficult to integrate into a 
diagnostic device with a small footprint.      
      We have recently developed a technology that utilizes SERS to circumvent the 
spectral overlap of fluorescence spectroscopy while retaining sensitivity and accuracy 
of LDR for SNP detection.
11
 Detection schemes utilizing SERS are advantageous over 
fluorescence as Raman peaks are approximately 1 nm
12
 full width half maximum 
(fwhm) while fluorescent labels can be 100 times larger fwhm.
13
  In addition to our 
LDR-SERS platform, Raman spectroscopy has been utilized for DNA identification 
and SNP detection using hybridization platforms 
14,15
 as well as PCR based systems.
16
 
Importantly, multiplex identification systems have been developed utilizing SERS 
technologies that require no additional data processing other than simple peak 
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recognition.
16-18
  
     Here we demonstrate the multiplex genotyping capacity of our LDR-SERS 
technology and how it may be used to identify multiple SNP alleles. Varying Raman 
enhancer and excitation wavelength conditions were tested to determine their effect on 
signal to noise ratio of each peak cluster. Additionally, the direct correlation between 
diagnostic peak intensity and template concentration was demonstrated. Finally, a 
three-plex detection system was demonstrated with a 10 pmol limit of detection.   
 
Materials and Methods: 
 
Ligase Detection Reaction: 
 
Template DNA used in LDR reactions was genomic DNA extracted from non-
diseased colon, DLD1, and SW1116 cell lines for WT, G12D, and G12A detection 
experiments respectively.  The oligonucleotide sequences of all the probes used in 
these experiments are shown in Table 1.  All DNA primers were synthesized 
(Integrated DNA Technologies Coralville, IA) and adapted by previous work done by 
Khanna et al.
4
.  Thermostable 9º North DNA ligase and buffer were purchased from 
New England Biolabs (Beverly, MA).  The LDR reaction contained the following in a 
10 μL reaction: 20 pmol of template, 100 pmol of each primer, 1 μL of 9º N DNA 
ligase, 1 μL of supplied 9ºN DNA ligase 10 X Buffer, and water to 10 μL.  The LDR 
reactions used the following thermocycler program in a MJ Research PTC-200 Peltier 
Thermo Cycler: 1) 90°C for 2 min 2) 90°C for 30 sec 3) 50°C for 4 min 4) Repeat 
Steps 2-3 29 times then 50°C for 10 min.  5) Hold at 4°C  
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LDR functionalization and purification:   
The completed LDR reaction mixture was treated with 2 μL of DMSO, mixed, and 
allowed to sit for 2 mins. 100 picomoles of the NHS ester of thioctic acid was added to 
the treated LDR reaction and allowed to react for one hr.  The reaction mixture was 
then added to 200 μL of 60 nm Ag or Au nanoparticles and allowed to react for 1 hr 
and purified as previously described.
11
  
 
Raman spectroscopy measurements:  
Raman measurements were made using an inVia Raman spectrometer (INVIA 
Medical Imaging Solutions, Ann Arbor, Michigan) coupled to a Leica microscope.   
The experiments were conducted by focusing the excitation laser on the electro-active 
microwell as previously described.
11
 
19
 The 488 nm and 785 nm laser lines were used 
as optical excitation sources and the scattered signal was collected by a Peltier-cooled 
CCD detector.  A 50 X (NA=0.55) objective lens was used to focus the laser beam 
spot onto the sample surface with diameter of about 2 μm.   Wave-numbers ranging 
from 1100 cm
-1
 to 1800 cm
-1
 were examined for all SERS experiments. 
 
Results and Discussion: 
     An example of our multiplex LDR-SERS scheme is presented in Figure 2-1.  An 
oligonucleotide primer, common to all haplotypes for a given gene locus, binds 
downstream of a SNP.  This primer contains an amine for conjugation to a Raman 
enhancing nanoparticle after ligation has occurred.  A second primer containing a 
Raman active fluorophore and a discriminating base at the 3’ end binds upstream of  
 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1:  A) Overview of LDR/SERS ligation B) Schematic of multiplex SERS 
spectra. Silver spheres represent silver nanoparticles and colored circle represent 
fluorophores.   
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the SNP, adjacent to the first primer.  This discriminating, terminal base allows for 
allele specificity, as ligation only occurs if the upstream primer matches perfectly with 
the DNA template. Therefore, Raman signal will only be detected if ligation of the 
two primers occurs, since the Raman enhancer must be very close to the signal source.  
Different Raman active fluorophores are placed on the SNP allelic specific primers, 
which produce a signature Raman profile as diagramed in Fig 1b. 
      As described in Table 1, a TAMRA fluorescent label was attached to the wild type 
discriminating primer while a fluorescein and 6-carboxyfluorescein (6-FAM) labels 
were attached to the G12D and G12A discriminating primers respectively.  Samples 
containing all three templates produce an aggregate spectrum that has elements of all 
Raman reporters, but diagnostic peaks of each marker can still be discerned and 
quantified.  After the ligation occurs, the Raman enhancer is attached to the DNA 
strand, purified, and then concentrated in an electroactive nanowell. 
11,19
 
      Upon examining the differences in spectra, several possible diagnostic peaks were 
identified with the most prominent at approximately 1315 cm
-1
, 1370 cm
-1
, and 1488 
cm
-1 
for fluorescein (G12D), TAMRA (WT), and 6-FAM (G12A) labeled DNA 
respectively.  In order to optimize the SERS output signal and resolution between 
diagnostic peaks, the interplay between laser excitation wavelength and nanoparticle 
enhancers was investigated using a two-plex model.  Figure 2-2a plots TAMRA 
labeled DNA SERS intensity as function of laser excitation wavelength and Raman 
enhancers.  While the 785 nm excitation source (Fig 2A3 & 2A4) did provide three-
fold more intense peaks at the 1500 cm
-1
 cluster in the TAMRA sample, the 488 nm 
excitation source gave much more distinct peaks, reducing the peak width of the 1370 
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cm
-1 
diagnostic peak by a factor of three in both the silver and gold enhanced samples.  
A similar pattern was seen for fluorescein-labeled DNA in figure 2-2b.  The 488 nm 
laser provided an approximately three-fold higher signal as compared to the 785 nm 
excitation source for the peak at 1650 cm
-1
 and a 1.4 fold average enhancement when 
comparing the silver enhanced samples.  This is most likely attributable to a resonance 
Raman effect, where both dyes are excitable to their first electronic state at 488 nm but 
not at 785 nm.
16
 
20
  Resonance Raman effects can greatly increase Raman signal, 
which has been previously shown in assays detecting DNA base changes using 
hybridization format.
14
 
     An average 1.33 SNR enhancement of silver compared to gold was achieved in the 
TAMRA sample excited at 785 nm.  In the fluorescein labeled sample, an average 3.2 
SNR was achieved over gold when excited at 488 nm.  SNR of the fluorescein labeled 
samples excited at 785 nm was not readily comparable in silver versus gold 
enhancements due to the large peak broadness of the gold enhanced samples.  The 
metal dependent, Raman enhancement trends conform to previously observed 
behavior that silver is often a better Raman enhancer than gold.
21
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Table 2-1. Primers used in LDR-SERS experiments 
Template/Primer Sequence for LDR (5’ – 3’) 
Common LDR 
Primer 
5Phos
1
/TGG CG/AmT
2
/ AGG CAA GAG TGC CTT GAC 
G12D Mutant LDR 
Primer 
GAA TAT AAA CTT GTG GTA G/FlurT
3
/T GGA GCT GA 
G12A Mutant LDR 
Primer 
GAA TAT AAA CTT GTG GTA G/6FAM
4
/T GGA GCT GC 
Wild type LDR 
Primer 
GAA TAT AAA CTT GTG GTA G/TAM
5
/T GGA GCT GG 
15Phos denotes a 5’ phosphorylation; 2AmT denotes an aminated thymine; 3FlurT 
denotes a fluorescein dT. 
4
6FAM denotes a 6-Carboxyfluorescein dT 
5
TAM denotes a 
TAMRA dT. The 3’ base in mutant and wild type LDR primers (bold and italic) allow 
for specific discrimination of the two templates 
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Figure 2-2: Investigation of Raman enhancers and excitation source.  Samples 
1 and 2 were excited at 488 nm while samples 3 and 4 were excited at 785 
nm.  Odd numbered samples contained silver Raman enhancers and even 
numbered samples contained gold Raman enhancers as indicated by colored 
spheres.  A) Wild Type TAMRA labeled DNA.  B) G12D mutant fluorescein 
labeled DNA 
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This effect is due to the localized surface plasmon resonance of the aggregated silver 
particles having a greater maximum absorbance than gold and better matching the 
excitation wavelength. Again, higher Raman signal output may be obtained by 
matching the excitation wavelength to the absorbance wavelength of the fluorescent 
label, inducing an electronic transition to achieve surface enhanced resonance Raman 
(SERRS).  Quantitatively maximizing Raman signal based on nanoparticle 
composition and excitation wavelength has been thoroughly analyzed previously.
22
 
Design and selection of Raman molecules for multiplex analysis have also been 
previously investigated.
23-25
  
    Figure 2-3 shows two-plex data obtained for a mixture of WT and G12D targets 
using both LDR primers.  Figure 2-3a shows the SERS spectra profiles of a mixture of 
WT and G12D with silver or gold as the SERS enhancer (silver for 1 and 3, gold for 2 
and 4) and excitation wavelength of 488 nm (1 and 2) and 785 nm (3 and 4).  The 
multiplex sample conformed to the trends observed in Figure 2-2, with silver 
nanoparticles demonstrating 1.5 and 2 fold SNR enhancement for the fluorescein and 
TAMRA diagnostic peaks respectively when excited at 488 nm as compared to gold.  
The 488 nm laser reduced the peak width of the fluorescein and TAMRA diagnostic 
peaks by a factor of 1.8 and 1.2 respectively as compared to the 785 nm excitation 
source for silver enhanced samples.  Figure 2-3b shows a resultant two-plex spectra 
with the fluorescein and TAMRA spectra overlaid, demonstrating that the diagnostic 
fluorescein peak at ~1315 cm
-1
 is clearly distinguishable from the diagnostic TAMRA 
peak at ~1370 cm
-1
, which identify the G12D mutant and wild type genotypes 
respectively.  These spectra were obtained from silver enhanced samples excited at  
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Figure 2-3: Two-plex SNP Samples.  A) Mixed genotype SERS spectra.  B) Overlay 
of singleplex SERS spectra with WT in dark grey and mutant in light grey against the 
multiplex spectrum in black.  TAMRA and fluorescein diagnostic peaks are 
highlighted with labeled arrows.  C) Diagnostic peak intensities of mix genotype 
samples, varying the LDR template concentration of mutant to wild type template 
DNA as: 1) 0.1:1 2) 0.5:1 3) 1:1 4) 3:1 5) 5:1.  D) Plot of template molar ratio against 
diagnostic peak intensity.  I denotes intensity, M denotes moles, T denotes TAMRA, 
and F denotes Fluorescein.   
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488 nm. Figure 2-3c depicts the correlation of SNP concentration to signal intensity.  
In the mixed sample, the population of mutant (fluorescein) to wild type (TAMRA) 
DNA template was varied in the LDR reaction of at ratios of 0.1:1, 0.5:1, 1:1, 3:1, and 
5:1 in samples 1-5 respectively.  As expected, as the ratio of mutant to WT SNPs is 
increased, the 1315 cm
-1
 signal increases while the 1370 cm
-1 
signal decreases. 
     Figure 2-3d plots the molar ratio of WT to mutant template concentration against 
signal intensity of the diagnostic peaks as obtained from Figure 2-3c.  A linear trend is 
generated with diagnostic signal intensity directly correlating to the genotype molar 
ratio.  Unlike PCR, LDR does not produce exponential amplification of the product 
since the product of the ligation is not a template for the LDR primers.  The signal is 
linear with the initial target concentration.  
     Figure 2-4 demonstrates three-plex capabilities of the system. In the presence of all 
three diagnostic primers, LDR reactions were run with one, two, or three templates 
then functionalized with silver nanoparticles and their Raman spectra analyzed. Figure 
2-4A1 shows a diagnostic peak for the G12D mutant (fluorescein) at approximately 
1315 cm
-1
 . Figures 2-4A2  and 2-4A3 are representative spectra for WT (TAMRA) 
and G12A (6-FAM) haplotypes respectively. While 1370 cm
-1
 was potentially a 
diagnostic peak for TAMRA-labeled WT templates it overlaps with the 6-FAM peak 
seen for the G12A allele. An alternative diagnostic peak for the WT spectrum can be 
seen at ~1225 cm
-1
 however and can be used for WT haplotype identification. The 
G12A haplotype has a unique diagnostic peak at ~ 1488 cm
-1
. Figure 2-4A4 
demonstrates that the presence of all three diagnostic primers in the reaction not 
inhibit two-plex detection, as diagnostic peaks for WT and G12D mutations are  
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Figure 2-4: Multiplex SNP Samples. A) 1. G12D (Fluorescein) Mutant 2) WT KRAS 
(TAMRA)  3) G12A (6-FAM) Mutant 4) WT & G12D 2-plex 5) WT, G12D, G12A 3-
plex. Dotted lines indicate diagnostic peaks. B) Dilution series of LDR three-plex 
containing variable amounts of template. 1) 20 pmol 2) 10 pmol 3) 5 pmol 4) 2 pmol 
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present. Figure 2-4A5 demonstrates detection of all three haplotypes with diagnostic 
peaks for all three alleles clearly present. Figure 2-4B shows a dilution series that 
demonstrates a 10 pmol limit of detection.  
 
Conclusions:   
Here we have demonstrated an important step toward a LDR-SERS detection platform 
for SNPs. This system allows accurate discrimination of multiple alleles, and does not 
require a microarray format or capillary electrophoresis.
26
  Additionally, it displays the 
ability to quantify SNP allelic ratios based on relative signal intensity.  This 
technology is an important advancement in moderate scale SNP detection as it retains 
the advantages previously shown with LDR and increases the potential for multiplex 
detection in a relatively simple technology platform.  SERS multiplex detection of 
oligonucleotides labeled with common fluorophore tags has been previously 
demonstrated.
27
 
28
  It is important to note that fluorophores are often used as Raman 
tags due to their wide availability on oligonucleotides, but any chromophore or 
molecule with a high Raman cross section and unique spectral signature could be used 
as a label.
29, 30
  This opens up a very large spectral space for detection and 
multiplexing possibilities.  Multiplexing is particularly amenable to this system 
because even if diagnostic peaks overlap, their sources can still be determined through 
spectral fitting analysis, which identifies peaks not discovered by linear analysis and 
direct observations. 
28
 Furthermore, isotopically different variants of a given probe 
may be detected as different signals allowing for further multiplexing.
31
 Due to the 
adaptability and sensitivity of our system, we believe our technology is a step towards 
 55 
an eventual point-of-care genotype analysis system for clinically relevant SNPs. In 
order to achieve this point-of-care goal, attachment of Raman enhancers to 
oligonucleotides prior to the ligase detection reaction must be achieved and is 
currently being investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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CHAPTER 3 
 
Fluorescence Quenching and Binding Kinetics of Lipophilic Stains in CTAB Coated 
Gold Nanorods 
 60 
Abstract: 
We have examined the fluorescence quenching and binding kinetics of the lipophilic 
stains Nile Red and IR-786 by CTAB coated gold nanorods. Analysis of quenching 
showed IR-786 was quenched approximately ten times more efficiently than Nile Red 
under identical conditions, due to its emission peak matching the absorbance plasmon 
of the gold particles. We additionally examined the binding characteristics of the 
stains to test their affinity for the CTAB coated nanorods using a surface plasmon 
resonance platform. Nile red and IR-786 displayed similar Kds of 10.3 ± 0.68 µM and 
13.33 ± 0.72 µM respectively, as determined by global fit analysis. Here we 
demonstrate the quenching ability of gold nanorods for lipophilic dyes, and for the 
first time, describe the binding characteristics of the stains using a surface plasmon 
resonance platform. This platform permits the measurement of analyte diffusion into 
bilayer-functionalized nanoparticles in real time with a high degree of analytical 
precision and demonstrates the ability to model nanorod bilayer trafficking kinetics 
under a variety of conditions. 
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Introduction: 
Cetyltrimethyl Ammonium Bromide (CTAB) coated nanorods have become 
important to the field of nanotechnology for their use in small molecule detection
(1)
, 
effects on cell morphology
(2)
, and cellular imaging.
(3)
 These particles are particularly 
interesting because of their bimodal absorbance plasmon, as well as their CTAB 
coating, which is located only along the longitudinal axis of the rods, leaving the 
terminal ends available for regiospecific functionalization.
(4-6)
  The longitudinal 
plasmon band of the particles is highly tunable,
(7),(8)
 becoming more red shifted as the 
aspect ratio of the particles is increased.
(9)
 This tunability is useful as the absorbance 
peak can be adjusted for Förster resonance energy transfer (FRET) or Raman 
experiments.
(10-12)
 While the fluorescence quenching mechanism of nanocrystals 
(quantum dots) by CTAB nanorods has been investigated,
(11),(13)
 the interaction of 
highly lipophilic fluorescent stains with CTAB nanorods has not previously been 
explored. Characterization of fluorescence quenching capabilities and binding kinetics 
of CTAB coated nanorods is highly relevant, as CTAB nanorods can be excellent 
carriers for various substances that interact with biological systems. They have been 
shown to selectively release rhodamine B
(14) 
as well as DNA
(15)
, depending on laser 
stimulation conditions. Nanorods functionalized with folate have been used for 
localized hyperthermic therapy demonstrating the importance of both biological 
functionalization as well as light absorption properties.
(16)
 CTAB itself has been 
shown to be a good carrier of biomolecules, carrying DNA vaccines for muscosal 
delivery,
(17)
 and have preferential uptake by tumor vasculature over healthy 
vasculature due to excess anionic lipids in the tumor vasculature.
(18)
 Here we 
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characterize the fluorescence quenching characteristics of CTAB nanorods with the 
stains Nile red and IR-786, and further investigate the binding kinetics of the stains, 
demonstrating the potential of SPR to be used as a model for analyte trafficking in 
nanorods. 
Nile red (Nile blue oxazone) is a well characterized, lipophilic stain originally 
described in 1907.
(19)
  It is strongly fluorescent, but only in hydrophobic environments 
and is generally used as a lysochrome.  In situ, Nile red allows for specific detection of 
intracellular lipid vesicles when excited at approximately 500 nm and yellow 
fluorescence is observed (515-560 nm).
(20)
  Stronger, red fluorescence that is less 
sensitive to the hydrophobicity of the environment is detected when Nile red is excited 
at approximately 550 nm and emission greater than 590 nm is observed.
(20)
  IR 786 is a 
cationic, lipophilic stain designed to absorb and emit in the near IR, avoiding the 
intrinsic autofluorescence of tissue when excited with visible light.  IR-786 has been 
shown to be particularly useful for studying myocardial blood flow
(21)
 as well as 
brown adipose tissue which regulates adaptive thermogenesis.
(22), (23)
  We have chosen 
to use Nile red and IR-786 due to the specific placement of their emission peaks and 
their lipophilicity.  The Nile red emission maximum falls between the two absorption 
peaks of the nanorods while the emission maximum of IR-786 closely matches the 
longitudinal absorbance maximum of the nanorods. This demonstrates how stains may 
be matched to particles of specific aspect ratios and absorbance peaks.  The stains 
were also chosen for their lipophilicity, assuring their interaction with the CTAB 
bilayer.  
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To examine the binding kinetics of each of the stains, a surface plasmon resonance 
platform was chosen. Examining the binding affinities of the dyes to the particles 
additionally demonstrates that the fluorescence quenching of the particles was a 
function of absorbance wavelength and not differential binding.  Surface plasmon 
resonance has been used extensively to characterize the binding of antibodies to 
immobilized antigens
(24-26)
 as well as small molecules to ligands
(27-29)
 and lipid 
bilayers.
(30-32)
  To our knowledge, this investigation is the first to test the binding of a 
ligand directly to a CTAB bilayer without other receptors such as surface protein
(33-35)
 
via surface plasmon resonance. This platform is useful because it applies broadly to 
surface functionalized nanoparticles that are used as carriers for non-covalently bound 
ligands. Other methods rely on fluorescence or specific functional groups to track 
ligand release while SPR simply relies on the change in refractive index as binding 
occurs. The combination of determining fluorescence quenching capability and the 
binding kinetics of almost any analyte that will bind the functionalization layer makes 
this platform an especially powerful tool for monolayer or bi-layer coated 
nanoparticles used as carriers.   
 
Experimental Section: 
    All reagents were purchased in the highest purity available. Silver nitrate, 
chloroauric acid, sodium borohydride, ascorbic acid, IR-786 iodide and Nile red were 
purchased from Sigma Aldrich (St. Louis, MO). Hexadecyl-trimethyl-ammonium 
bromide (CTAB) was purchased from Fluka (Sigma Aldrich, St. Louis, MO). It has 
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been noted that there can be significant variability in successful synthesis of CTAB 
coated nanorods due to lot to lot variability of CTAB.
(36) 
We therefore report the 
CTAB catalog number, lot number and filling code as 52365, 1340943, and 53407250 
respectively. Reichert Analytical Instruments (Depew, NY) provided bare, gold SPR 
chips (Catalog no. 13206060).   
Nanorod Preparation and Characterization.  
Biaxially coated CTAB Nanorods were prepared and purified as described 
previously.
(37) (1)
 A 40.24 ± 1.33 x 13.68 ± 0.98 nm size and rod shape were confirmed 
by transmission electron micrograph on a JEOL 1200EX transmission electron 
microscope as seen in Figure 3-1, using 200 mesh grids. Variability in nanorods size is 
denoted as standard deviation and was determined by measuring 20 different rods in 
each of 10 different fields of view at a given magnification. After concentration via 
centrifugation at 8000 G for 10 minutes and resuspension in water, the final 
nanoparticle concentration was found to have an absorbance equivalent to 16.5 AU at 
775 nm which corresponds to approximately 2.0 mg/ml of particles. Mass of the 
particles was characterized by determination of their dry weight after purification from 
excess CTAB.  
 
Fluorescence Measurements.  
Fluorescence Measurements were taken on a Perkin Elmer LS50B fluorimeter. All 
samples were prepared identically and contained 1 mM CTAB, 50 nM Nile Red or IR-
786, 0.05% (v/v) DMSO and nanorod concentrations as noted in the text.  Fluorescent 
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scans were taken from 550 nm to 875 nm. Each sample was measured 10 times and 
their output signals averaged. Three independent samples were run for each 
concentration and stain. Excitation slits were set to 10 nm, emission slits were set to 5 
nm, and dwell time was 500 nm/min. Nile Red was excited at 545 nm and IR-786 was 
excited at 745 nm.  
Surface Plasmon Resonance Measurements.  
Surface plasmon resonance measurements were taken on a dual channel Reichert 
Surface Plasmon Resonance Spectrophotometer SR7000DC. Bare gold SPR chips 
were cleaned with ethanol prior to use and dried with nitrogen gas. The chip surface 
was functionalized by flowing Buffer A (1 mM CTAB and 0.05% (v/v) DMSO) in 
aqueous solution through both channels at 25 µl/min overnight. This same buffer was 
used as sample buffer between injections. Samples containing Buffer A and varying 
concentrations of Nile Red or IR-786 were injected for 540 seconds, and after this 
time buffer was again applied and the sample was allowed to dissociate for 200 
seconds. The chip was then washed with water for 200 seconds, clearing off the 
CTAB bilayer and sample. Buffer A was then flowed over the chip for 200 seconds to 
refunctionalize the chip. Response curves were aligned, cleaned, and analyzed for 
equilibrium fit in Scrubber (BioLogic Software, Campbell, Australia). Scrubber was 
also utilized to subtract out the refractive index change caused by DMSO in the 
solvent system, by utilizing the “DMSO” function and running a DMSO standard 
curve. BIAevaluation (Biacore Life Sciences, Piscataway, NJ) was utilized for global 
fit analysis of the SPR data.   
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Results and Discussion: 
UV/Vis Absorption and Fluorescence Quenching:  
CTAB coated gold nanorods were prepared by standard seed mediated growth 
methodology and characterized by TEM (Figure 3-1). The size of the rod shaped 
particles was determined to be 40.24 ± 1.33 x 13.68 ± 0.98. An absorbance spectrum 
of nanorods was taken from 400 to 800 nm (Figure 3-2) showing the bimodal 
absorbance peaks characteristic of nanorods. The aspect ratio of these rods was 
approximately 3, with absorption maxima at approximately 550 nm and 800 nm for 
the latitudinal and longitudinal absorption plasmons respectively. The intensity of the 
longitudinal peak was approximately 2.8 times more intense than the latitudinal 
absorption peak. The absorption minimum of the nanorods was noted to be 
approximately 650 nm. In order to test the fluorescence quenching capacity of the 
rods, the stains Nile red and IR-786 were chosen to fall between the two absorbance 
peaks and match the longitudinal absorbance maximum of the nanorods respectively. 
Both Nile Red and IR-786 require a non-polar environment to fluoresce, so a 
relatively non-polar solvent of 0.05% (v/v) DMSO and 1 mM CTAB in water was 
used. This solution is above the critical micellular concentration of CTAB(38), which 
will induce micelle formation and fluorescence from the stains.   This buffer was 
found to provide high levels of fluorescence for both stains, and inclusion of CTAB in 
the buffer also prevents the nanorods from precipitating which occurs at lower levels 
of CTAB in solution. Nile red was excited at 545 nm, producing an emission  
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Figure 3-1.TEM image of CTAB coated nanorods at 89000x 
magnification. 
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Figure 3-2: UV/Vis absorption spectrum of nanorods (solid grey line, AU) and 
fluorescent emission peaks of Nile red (black circles, RFU) and IR-786 (black 
triangles, RFU).  The Nile Red falls between the two absorbance plasmons of 
the nanorods while the IR-786 matches the longitudinal absorbance plasmons.  
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maximum around 625 nm while IR-786 was excited at 770 nm producing an emission 
maximum around 790 nm as seen in Figure 3-2.  Additionally, Figure 3-2 illustrates 
how the emission maxima of Nile red and IR-786 falls between absorbance peaks and 
match the latitudinal absorbance maximum of the nanorods respectively. 
Increasing amounts of nanorods were added to buffer solutions containing 50 nM 
stain to test their fluorescence quenching capacity.  Figure 3-3 shows a fluorescence-
quenching curve plotting particles added against the percent of control fluorescence at 
525 nm for Nile red and 790 nm for IR-786. A saturation curve was observed for both 
stains with Nile red reaching complete quenching after 104 µg of particles had been 
added while IR-786 was nearly completely quenched after only 10 µg of particles had 
been added. This correlates to an approximate tenfold increase in quenching capacity 
of IR-786 over Nile red. This would be expected as the absorbance maximum of the 
rods matches well with the emission maximum of the IR-786. Due to the fluorescence 
quenching behavior exhibited by the nanorods, we were interested in the binding 
kinetics of stains to the rods. Additionally, determining the relative binding affinities 
would differentiate whether quenching was only a function of absorbance-emission 
matching or whether differential binding of the stains contributed.  
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Figure 3-3: Fluorescence quenching curve of Nile red (grey diamonds) and IR-
786 (black circles) by nanorods, plotting particles added against percent of 
control fluorescence quenched at respective emission maxima. Both dyes 
reached saturation, indication complete quenching, with IR-786 being quenched 
approximately 10 times faster than Nile red.  
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Binding Kinetics of Nile Red and IR-786: 
 To investigate the binding kinetics of the lipophilic stains to CTAB coated 
nanorods, a bare gold SPR chip was functionalized with CTAB and the binding 
kinetics of the stains were determined by surface plasmon resonance. Figure 3-4 
depicts the observed response curve when functionalizing the gold SPR chip for the 
first time with the CTAB buffer solution. In Figure 3-4, the water sections of the 
chromatogram illustrate the change in response from water being injected through 
sample valve then the buffer line as the sample valve is shut off. During the bilayer 
formation phase, the running buffer was changed to CTAB/DMSO solution and a 
rapid increase in response is observed as CTAB begins to functionalize the chip. 
Interestingly, without any change in conditions, another response spike is seen near 
the end of segment CD.  The initial upward trend corresponds to the accumulation of 
CTAB micelles on the gold chip surface. It is safe to assume CTAB micelle formation 
as the solution is above CTAB‟s critical micelle concentration of 0.8 mM.(38) The 
second spike in refractive index response is most likely attributable to a change on the 
chip‟s surface from a conglomeration of micelles to a CTAB bilayer. The removal 
section of the graph illustrates a water injection to clear the chip. In the 
refunctionalization phase, water injection was stopped and the CTAB buffer was again 
passed over the chip. The response curve immediately returned to the bilayer level of 
response. The micellular intermediate only appeared during the first functionalization 
of a new chip, never after subsequent clearings with water. This behavior was 
observed with several different chips used. The micellular intermediate  
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Figure 3-4:  Initial functionalization of SPR chip plotting flow time against 
signal response at 25 µl/min. As noted on the graph water is flowed through the 
sample valve then the buffer line. The chip is then functionalized with CTAB 
and stripped with water. The chip is then refuctionalized and buffer is allowed to 
flow overnight.  
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was not observed when a flow rate faster than 25 µl/min was used to functionalize 
the chip.  
After establishing the CTAB bilayer on the SPR chip, Nile red or IR-786 were 
injected in increasing concentration from 20 nM to 1 uM. Note that the injection 
buffer containing the dyes also contained CTAB above the critical micelluar 
concentration, thus the dyes were contained in micelles and were not exposed to 
aqueous solution. Figure 3-5A plots the response level against time as Nile red was 
injected and allowed to dissociate from the CTAB functionalized chip.  The solid, 
black lines represent the response recorded by the instrument while the dashed, grey 
lines demonstrate a global fit performed on the data using the Langmuir model built 
into the Biaevaluation software. Figure 3-5B plots increasing analyte concentration 
against response levels detected at equilibrium. The Langmuir model built into 
Scrubber SPR analysis software was used to fit the curve to the data points in Figure 
3-5B. Both the global fit as seen in Figure 3-5A and the equilibrium fit in Figure 3-5B 
correlate well with a Langmuir binding profile. Utilizing Scrubber SPR analysis 
software, an equilibrium fit was first performed using the data from Figure 3-5B to 
determine an equilibrium dissociation constant (KDeq) of 9.2 µM of Nile red binding to 
CTAB with a Ka of 1.1 x 10
5 
M
1-
s
-1
. The Langmuir curve fit the model well with a chi-
square value of 1.92. A chi square value of less than ten demonstrates a good 
statistical fit for sensograms with normal noise levels.  
The response curves were then analyzed with BIAevalution using a global fit 
analysis. A Langmuir model, a Langmuir model with mass transport, and a competing 
reaction model were used for data fitting analysis. Due to the small molecular weight  
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Figure 3-5: Nile red SPR data. A) Raw response curve over time depicting 
injection, equilibrium, and dissociation. Black, solid lines plot signal recorded 
while grey, dashed lines depict a Langmuir fit to the data. Response curves 
correspond to concentrations of 20 nM, 50 nM, 75 nM, 100 nM, 200 nM, 500 
nM, 750 nM, and 1 µM. B) Plot of Nile red concentration against response at 
equilibrium. Langmuir fit seen in grey.  
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of Nile Red and observed Ka of less than 1.0 x 10
6 
M
1-
s
-1
, mass transport 
significantly affecting kinetic values was unlikely but considered.
(39)
 As expected, no 
meaningful fit was obtained. In the competing reaction model, a large variety of 
molecular weights and concentrations were modeled with no meaningful fit. The 
Langmuir model without mass transport provided the only meaningful fit, as seen 
from the chi-square values in Table 3-1. The global fit of Nile Red binding produced a 
KD of 10.3 ± 0.68 µM with a Ka of 1.01 x 10
5 
M
1-
s
-1 
and a chi-square value of 1.78. 
This demonstrates the global fit utilizing a Langmuir model matched the data very 
well and produced a dissociation constant very similar to that seen from the 
equilibrium fit. The IR-786 data was analyzed in a similar manner as seen in Figure 3-
6, demonstrating a KDeq of 12.82 µM and a chi-square value of 2.46 for the 
equilibrium fit. Global fit analysis again showed that a Langmuir model best fit the 
data, as opposed to the competition and Langmuir with mass transport models (Table 
3-1). A KD of 13.33 ± 0.72 µM was determined for IR-786 using the global, Langmuir 
fit with a chi-square value of 4.53.  The slightly higher chi-square values for the IR-
786 data as compared to the Nile Red data are due to the poorer fit at higher 
concentrations but still fall well within the ninety-five percent confidence index. 
Experiments were repeated at higher flow rates but no statistically significant change 
in binding profile was observed.  
     SPR experiments indicate that Nile Red and IR-786 bind to CTAB coated gold 
SPR chips with similar affinity, having KDs in the low micromolar range. These 
studies also indicate the stains tend to bind in a Langmuiric fashion to the CTAB  
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Stain Model Chi Square 
Value 
IR-786 Langmuir (1:1) 4.51 
IR-786 Langmuir with Mass 
Transfer 
21.5 
IR-786 Competing Reaction 213 
Nile Red Langmuir (1:1) 1.78 
Nile Red Langmuir with Mass 
Transfer 
28.6 
Nile Red Competing Reaction 177 
Table 3-1: Chi square values for global fit of SPR response curves.  
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Figure 3-6: IR-786 SPR data. A) Raw response curve over time depicting injection, 
equilibrium, and dissociation. Black, solid lines plot signal recorded while grey, 
dashed lines depict a Langmuir fit to the data. B) Plot of Nile red concentration 
against response at equilibrium. Langmuir fit seen in grey. 
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bilayer. The determination of similar binding profiles of the two stains is important 
as it excludes differential binding profiles as the cause of the nanorods to quench IR-
786 fluorescence ten times better than Nile red. The SPR studies were also able to 
show a transition from micelle to bilayer on the SPR chip, demonstrating that binding 
to the SPR chip was a good proxy to binding directly to CTAB coated nanorods.  
 
 
Conclusions: 
We concluded that CTAB coated nanorods are able to quench fluorescence of the 
lysochromes Nile red and IR-786, with IR-786 being quenched ten times more 
efficiently because its emission maximum matches the absorbance maximum of the 
nanorods. We additionally determined the dissociation constants of Nile red and IR-
786 to be 10.3 ± 0.68 µM and 13.33 ± 0.72 µM respectively via surface plasmon 
resonance, which excludes preferential binding as the cause of different fluorescence 
quenching ratios. While conducting SPR experiments, we were also able to 
demonstrate a transition to a CTAB bilayer upon primary functionalization of the SPR 
chip. It is important to note, that although a control containing only CTAB micelles 
was not run during the SPR experiments, the effect of micelles during dye binding 
events does not alter the kinetics measurements because the curve fitting model 
accounts for the buffer baseline signal, which contains CTAB micelles. Since the 
buffer contained the same CTAB micelluar concentration as the dye solutions, the 
effect of the micelles was subtracted by the curve fitting software when a baseline was 
established and all response curves were normalized to that baseline. The lack of 
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influence from micelle binding on dye kinetics can be further extrapolated from the 
functionalization of the chip in Figure 4 and the signal response from Figures 5 and 6.  
During functionalization of the chip, a response intensity of only approximately 1.5 
was obtained. At all concentrations measured, a higher equilibrium response was 
obtained as compared to the micelles alone. Since these values were used to fit KDeq, 
and they fit the langmuiric model extremely well, this would further argue that the 
effect of micelle trafficking during dye binding events does not have a significant 
effect on dye dissociation constant measurements. Overall, the information gathered 
here demonstrates the potential for the energy-coupling and physical interactions of 
hydrophobic, biological stains with nanorods due to the high degree of tunabilty of rod 
absorption and the wide selection of stains available.  
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CHAPTER 4 
SELENOCYSTEINE AS A pH DEPENDENT, HETEROBIFUNCTIONAL LINKER 
FOR PROTEIN CONJUGATION WITH SINGLE RESIDUE SELECTIVITY 
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Abstract: 
 
We have developed a protein conjugation system that selectively functionalizes a 
protein through its C-terminus in a pH dependent manner, by fusing it to a self-
splicing protein element known as an intein.  This system is advantageous over non-
specific functionalization systems such as EDC/NHS chemistry in that the linkage can 
occur at only one amino acid. The system uses selenocysteine (Sec) as both a 
cleavage-inducing agent for the intein and heterobifunctional linker. Maltose binding 
protein (MBP) fused to the Mxe gyrase A intein from Saccharomyces cerevisiae was 
expressed in E. coli. Sec was used to induce cleavage of MBP from the intein, in both 
lysate and while bound to a chitin chromatography column, leaving the Sec covalently 
bonded to MBP. MBP lysate and purified MBP were selectively labeled at pH 5 by 
reacting the selenocysteine tagged protein with maleimide labeled fluorescein and 
maleimide labeled nanoparticles. The system was further verified by expressing A33 
single chain antibody (ScFv) in Pichia pastoris fused to the Mxe gyrase A intein with 
a C-terminal 6x-His tag. The ScFv was cleaved and tagged with the Sec then reacted 
with maleimide labeled fluorescein. The fluorescein functionalized ScFv successfully 
labeled SW1222 cancer cells as determined by FACS, demonstrating the efficacy of 
the system.  
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Introduction: 
 
Inteins are self-splicing protein elements that are very similar to introns in mRNA. 
They were originally discovered in Saccharomyces cerevisiae
(1, 2)
 when two groups 
were studying the VMA1 gene. The gene encodes a protein expected to be 118 kDa but 
instead produces a 69 kDa active product and a 50 kDa secondary protein. Through 
mRNA and protein sequence analysis, it was determined that the two outer catalytic 
domains (exteins) were spliced together post-translationally and the 50 kDa protein 
was spliced out (intein). Inteins splice themselves out through a multistep 
transesterification-succinimide release process that relies on a conserved cysteine and 
serine in the N and C exteins respectively.
(3)
 The Sce VMA1 intein has been used 
extensively for biotechnology purposes since Chong et. al removed the conserved 
serine from the Sce VMA1, allowing cleavage to be induced in vitro by a reducing 
reagent such as DTT.
(4)
 The system was adapted by New England Biolabs as a 
purification system, allowing users to purify proteins without having any permanent 
affinity tag or having to use a protease to cleave the tag.
(5-8)
 Cleavage with DTT or 2-
mercaptosulfonic acid (MESNA) also allows the protein to be functionalized through 
intein mediated protein ligation (IPL).
(9, 10)
 The thioester created when MESNA 
liberates the protein from the intein can react with any cysteine to form a peptide 
bond, thus IPL allows the protein to be functionalized with peptides, protein, or any 
small molecule containing a cysteine or cysteine like moiety.  
     IPL has also been used to introduce selenocysteine into proteins by cleaving the 
protein of interest from the intein with a thiol and a selenocysteine labeled synthetic 
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peptide mixture, yielding the protein tagged with the selenocysteine labeled 
peptide.
(11)
 Sec is a rare amino acid in mammals and is a desirable functional group in 
vitro. Sec is more nucleophilic than Cys and its pKa is only 5.2 while Cys has a pKa 
of 8.3.
(12)
 This means that at relatively low pH values, Cys will be protonated while 
selenocysteine will still be reactive. Sec also has a much higher redox potential of  -
488 mV as compared to -233 mV of cysteine.
(13)
 In addition to IPL, selenocysteine has 
been added to proteins through a variety of chemical and recombinant methods. Serine 
residues have been converted to Sec chemically
(14)
 through activation with PMSF and 
hydrogen selenide. Selenocysteine labeled antibodies have been produced 
recombinantly in mammalian cell lines by engineering in the Sec Insertion Element 
(SECIS) into the 3‟ UTR, which suppresses the UGA stop codon and allows Sec 
insertion.
(15, 16)
 The SECIS element functions by forming secondary structure in the 
mRNA, which recruits cis and trans acting elements to insert Sec.
(17)
 Selenocysteine 
containing proteins have also been expressed in E. coli using an engineered SECIS 
element, a selenite substrate, and co-expression of the selA, selB, and selC genes 
which encode the selenocysteine synthase, the translation elongation factor SELB, and 
the tRNA
Sec
 respectively. The system produced an enzyme with 25% of the native 
enzyme‟s specific activity with a yield of 20 mg/L of culture.(18) A similar approach 
was used to produce glutathione S-transferase in E. coli internally labeled with 
selenocysteine at a yield of 2.9 mg/L of culture.
(19) 
           
     We present an amino acid specific, in vitro approach to label proteins with Sec by 
using the nucleophilicity of free Sec to cleave the target protein from an intein tag and 
simultaneously label the protein with Sec at its C-terminus. The protein can then be 
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further functionalized by combining it with any reactive functional group, such as a 
maleimide labeled fluorophore or surface (Figure 4-1). Conjugation only occurs at the 
Sec residue by using thiol and Se
-
 reactive linkers and titrating the pH such that only 
Sec is charged by taking advantage of its low pKa.  This system is advantageous over 
in vivo systems in that it does not rely upon stop codon suppression, where many 
peptides are cut short instead of including the Sec amino acid. The system is also 
advantageous over synthetic and semi-synthetic methods in that selenium or Sec 
containing peptides do not have to be synthesized at considerable expense. Here we 
demonstrate cleavage of MBP-intein fusions by Sec, Sec dependent functionalization 
of MBP with maleimide labeled fluorescein in bacterial lysate and purified Sec-MBP, 
and functionalization of maleimide labeled nanoparticles. We additionally demonstrate 
the scope of the system by using Sec to purify a His tagged, A33 ScFv-Intein fusion 
and subsequently label it with fluorescein. The labeled antibody was then used for 
FACS with cells bearing the A33 cancer antigen and performed almost as well as a 
commercially available antibody. This system provides an easy way to purify, label, 
and conjugate proteins in an amino acid specific fashion.     
 
Materials and Methods: 
 
Expression of MBP-Intein-CBD: 
The plasmid pMXB10, a derivative of pTXB1, was obtained from New England 
Biolabs (Ipswich, MA). It contains maltose binding protein fused to the Mxe A intein  
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Figure 4-1. Selenocysteine Mediated Intein Cleavage Mechanism. N-
terminal cysteine of the intein undergoes a N-S acyl shift making the 
carbonyl carbon very electropositive. In this arrangement, selenocysteine 
attacks the carbonyl carbon and cleaves the target protein-intein peptide 
bond. The target protein with the attached selenocysteine undergoes another 
rearrangement such that the Se moves to the side chain position, leaving it 
free to react. Figure adapted from New England Biolabs. 
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and a chitin binding domain (CBD) under control of the T7 promoter. The plasmid 
was transformed into BL21(DE3) E. coli cells and selected with ampicillin. A 
transformed colony was picked and inoculated into a 5 ml LB-Amp culture that was 
subsequently incubated overnight at 37°C. 200 µl of the overnight culture was 
inoculated into 20 ml of LB-Amp in a baffled flask and was shaken at 37°C until an 
OD600 of 0.6 was reached. Expression was induced with 0.35 mM IPTG for 3 hours 
after which time the cells were chemically lysed and the soluble fraction collected. 
Lysate was stored at 4°C. The lysate was resolved on a Bio-Rad (Hercules, CA) “Any 
kD” SDS-PAGE gel that was stained with Invitrogen SimplyBlue Safe Stain 
(Carlsbad, CA). An identical gel was transferred to nitrocellulose and a western blot 
was performed using HRP conjugated anti-MBP. Protein concentration was 
determined by Bradford Assay reagent as per the manufacturer‟s directions (“Sigma-
Aldrich” St. Louis, MA). 
 
MBP-Intein cleavage & Fluorescent Labeling from Bacterial Lysate: 
L-selenocystine (Sigma Aldrich, St. Louis, MO) was reduced to L-selenocysteine and 
intein cleavage was induced by allowing 80 μl ethanol, 160 μl TCEP (50 mM), 320 μl 
pH 5 sodium citrate buffer (20 mM), 1.6 mg selenocystine and 60 μl MBP lysate (~5 
mg/ml) to mix in a small glass vile for two hours. The L-selenocystine lost its yellow 
color upon reduction. To this solution, approximately 0.5 mg of fluorscein-5-
maleimide (Thermo-Fisher, Rockford IL) was dissolved and allowed to shake via 
rocker for two hours in the dark at room temperature. The non-selenocysteine control 
was reacted in the same manner as the successful conjugation but the buffer system 
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contained 80 μl ethanol, 50 μl 100 mM MESNA, 320 μl pH 5 sodium citrate buffer 
(20 mM), and 60 μl MBP lysate (~5 mg/ml). After conjugation, the protein was 
resolved on two Bio-Rad “Any kD” SDS-PAGE gels. One was stained with Invitrogen 
SimplyBlue Safe Stain while the other was imaged fluorescently with a Bio-Rad 
GelDoc system under UV excitation. Labeling efficiency was calculated as per the 
manufacturer‟s protocol for fluorscein-5-maleimide.  
 
MBP- Intein cleavage & Fluorescent Labeling from Purified MBP: 
Chitin beads were obtained from New England Biolabs and packed at 1 ml/min into a 
C10-10 column (GE Healthcare, Piscataway, NJ) to a bed height of approximately 3 
cm using an Akta Explorer (GE Healthcare, Piscataway, NJ) run by Unicorn Software 
(GE Healthcare, Piscataway, NJ). MBP-Intein-CBD lysate was diluted to 1.5 mg/ml 
with 25 mM pH 7 sodium phosphate buffer. 6 ml of the diluted lysate was loaded at 
0.4 ml/min. The column was then washed with 3 column volumes of the 25 mM 
citrate buffer at pH 5 at 0.5 ml/min. A selenocysteine solution containing 1.6 ml 
ethanol, 6.4 ml pH 5 citrate buffer (25 mM), 16mg Se-Se, 1 ml TCEP (50 mM) was 
prepared and allowed to stir for 2 hours. After stirring, one column volume of this 
solution was added to column and allowed to sit for one hour, after which the solution 
was eluted off the column and collected. 0.5 mg of fluorscein-5-maleimide was added 
to the eluted solution and was rocked in the dark, at room temperature for two hours. 
0.5 mg of fluorscein-5-maleimide and 0.5 ml of elution buffer were added to 2 ml of 
wash fraction and rocked for one hour in the dark. Finally, 0.5 mg of fluorscein-5-
maleimide was added to 2 ml of the wash fraction and rocked in the dark for 1 hour 
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without adding selenocysteine. The solutions were then resolved by SDS-PAGE and 
imaged fluorescently in a manner identical to the lysate. Total protein concentrations 
for all fractions were determined by Bradford assay.  
 
MBP Labeling of Gold Nanoparticles: 
0.8 nm “Undecagold” nanoparticles functionalized with maleimide were obtained 
from Nanoprobes Inc. (Yaphank, NY) and were re-suspended in 1 ml of ultra-pure 
water from its lyophilized state. Purified MBP bound to Sec was prepared as described 
in the previous section, without adding fluorescein. A second batch of purified MBP 
was also prepared using 10 mM MESNA supplemented with 5 mM NaOH in 25 mM 
citrate buffer (pH 5) to elute the protein from the column instead of Sec. After elution 
the preparation was titrated to pH 5. Four solutions were prepared in 1.6 ml centrifuge 
tubes containing (1) 50 μl Sec Eluted MBP, 200 μl Ultrapure Water (2) 200 μl Mal.-
Nanoparticles, 50 μl Ultrapure Water (3) 200 μl Mal.-Nanoparticles, 50 μl Sec eluted 
MBP (4) 200 μl Mal.-Nanoparticles, 50 μl MESNA eluted MBP. All four solutions 
were rocked for two hours in the dark. At the end of the particle incubation, 
nitrocellulose was incubated in a 1:1:8 - NuPage Transfer Buffer (Invitrogen, 
Carlsbad, CA):methanol:water solution for 10 minutes after which time the excess 
solution was removed while keeping the membrane slightly damp. 5 μl of each 
solution was spotted onto a separate spot on the activated nitrocellulose and allowed to 
bind for 30 minutes then aspirated off. The blot was briefly washed with blocking 
buffer and an image was taken at this point. A western blot procedure was then 
performed using the WesternBreeze Chromogenic Immunodetection Kit (Invitrogen, 
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Carlsbad, CA) using Anti-MBP-HRP as the primary antibody. After development of 
the western blot, a second image was taken.  
 
Production of A33 ScFv-Intein-His: 
The amino acid sequence for the single chain antibody against the A33 cancer antigen 
was obtained from previous work by our group.
(20)
 This sequence was fused in frame 
with the amino acid sequence for the Mxe mini-intein and a 6x-His tag was added to 
the C-terminus.
(21)
 It is important to note that the efficiency of intein cleavage is 
highly dependent upon the amino acid immediately upstream of the intein, and an 
alanine or other readily cleavable amino acid should be inserted if the last amino acid 
in the target protein is problematic, such as a proline.
(21)
 This sequence was then codon 
optimized for expression in the methanotropic yeast Pichia pastoris and synthesized 
by Genscript Technologies Inc (Piscataway, NJ). The construct was then subcloned 
into the pPiczA P. pastoris expression vector and transformed into a GS115 P. 
pastoris strain under Zeocin selection. Transformants were picked and grown for 72 
hours at room temperature while shaking in 50 ml of MMHA medium.
(22)
 0.25% (v/v) 
methanol was added every 12 hours as the cell‟s only carbon source at which time 
intracellular and supernatant samples were collected. 
 
Purification and Conjugation of A33 ScFv-Intein-His for FACS: 
After 72 hours of growth, the P. pastoris cells were pelleted by centrifugation and 
were re-suspended in breaking buffer and lysed as previously described.(26) The 
Pichia lysate was then clarified by centrifugation at 14000 g and the supernatant 
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collected. 25 ml of the lysate was then loaded onto a 5 ml HisTrap FF Column (GE 
Healthcare BioSciences, Uppsala Sweden) at 2 ml/min. The column was then washed 
with 3 CVs of 25 mM sodium phosphate buffer at pH 7.4. The bound A33 was then 
eluted by intein cleavage with Sec elution buffer as described above and was stored at 
4°C. After elution, the column was regenerated by washing with 1 CV of 0.1 M EDTA 
followed by a rinse with 5 CVs ultrapure water. The column was then recharged with 5 CV 
of 0.1 M nickel sulfate and rinsed with 10 CV of ultrapure water. A second batch of 
lysate was loaded onto the column and washed as described. It was then eluted with 1 
CV of 0.5 M Imidazole in 25 mM citrate buffer so as to elute the whole construct 
without inducing intein cleavage. After elution, the pH of both fractions was adjusted to 
pH 5.    
 
Fluorescence Activated Cell Sorting Assay: 
For use in FACS, SW1222 human colorectal cells were grown in GIBCO minimum 
essential medium supplemented with fetal bovine serum, L-Glutamine, Penicillin, and 
streptomycin. The adherent cells were trypsinized, pelleted and resuspended at 10 
million cells/ml. 100 μl of cell suspension was added to 4 separate tubes. The cells in 
the first tube were labeled with rabbit Anti-A33 monoclonal antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) then goat anti-rabbit IgG-FITC secondary antibody 
as per the manufacturer‟s recommendations for FACS. The second tube of cells was 
treated with approximately 1 μg of Sec eluted A33 ScFv and 0.5 mg of  fluroscein-5-
malimide. A third tube of cells was treated with approximately 1 μg of imidazole 
eluted A33 ScFv and 0.5 mg of fluroscein-5-malimide. A fourth tube contained 100 μl 
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of untreated cells. Both A33 treated tubes were allowed to react 1 hour on ice after 
which the excess antibody and fluorophore were removed by two wash and 
centrifugation cycles. All four cell treatments were tested using fluorescence-activated 
cell sorting on a Beckman Coulter flow cytometer using standard procedures in 
triplicate. 
 
Results and Discussion 
MBP-Intein-CBD Expression: 
A MBP-intein-CBD fusion was expressed in BL21(DE3) E. coli and used as a model 
for selenocysteine mediated intein cleavage and functionalization of proteins. The 
soluble fraction of the induced, clarified lysate had a total protein concentration of 
5.61 mg/ml as determined by Bradford assay. Expression of the MBP-Intein fusion 
was successful, as determined by Coomassie stained SDS-PAGE  (Figure 4-2A). The 
induced, insoluble fraction of the induced lysate may be seen in Lane 1 of Figure 4-
2A. A strong band at 72 kDa indicates expression of the full MBP-intein-CBD and a 
weak band at 41 kDa indicates some autocatalytic cleavage of the intein. Since the 
protein was found within the insoluble fraction it means that some of the recombinant 
protein was driven into inclusion bodies during overexpression and was not readily 
available for use. Lane 2 of Figure 4-2A shows the soluble, induced expression 
fraction. Another strong band at 72 kDa indicates full construct expression with a 
weaker cleaved band appearing again at 41 kDa. It is not surprising the auto-cleaved 
band is stronger in the soluble fraction, as it is more available for cleavage than in 
inclusion bodies where it is relatively protected. Lane 3 is the un-induced insoluble  
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Figure 4-2. Expression of MBP-Intein-CBD fusion in BL21(DE3) Escherichia 
coli. Lanes 1-4 correspond to induced insoluble, induced soluble, uninduced 
insoluble, and uninduced soluble fractions respectively. L denotes ladder. A) 
Coomassie stained SDS-PAGE gel. B) Western Blot of SDS-PAGE gel using 
anti-MBP HRP.  
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fraction. No MBP bands are  easily seen, indicating there is almost no MBP present in 
the uninduced, insoluble fraction, which is expected. No MBP can be easily identified 
in lane four which corresponds to the un-induced soluble fraction. Identity of the MBP 
fusion construct was confirmed with an anti-MBP western blot (Figure 4-2B). Lanes 
in Figure 4-2B correspond directly to lanes in Figure 4-2A. The more sensitive 
western blot detected some expression in both uninduced fraction, indicating some 
leaky expression from the T7 promoter. 
 
Selenocysteine Cleavage & Labeling of MBP-Intein-CBD from Lysate: 
After establishing expression of the MBP-Intein-CBD fusion, selenocysteine was 
tested to determine its ability to induce intein cleavage and subsequently label MBP 
with maleimide conjugated fluorescein. The Coomassie stained SDS-PAGE gel in 
Figure 4-3A shows intein cleavage from the fusion protein lysate while the fluorescent 
image in Figure 4-3B demonstrates pH and selenocysteine dependency of the labeling 
system. Lane 1 in Figure 4-3A is a control reaction of MBP-Intein-CBD lysate, treated 
with 2-mercaptosulfonic acid (MESNA) in pH 5 citrate buffer with a small amount of 
base, without selenocysteine. This was designed to induce cleavage at a higher pH 
then be titrated to pH 5 with prior to exposure to maleimide-fluorescein. By inducing 
cleavage without selenocysteine then titrating the reaction to pH 5, it demonstrates the 
pH selectivity of the system. At pH 5 the thiol in the MESNA tag is protonated and 
therefore unable to react with the maleimide labeled fluorescein, as seen from the lack 
of fluorescent band in Lane 1 of Figure 4-3B. The Sec cleavage reaction in pH 5 
citrate buffer is show in Lane 2 of Figure 4-3A. The cleavage of the MBP-Intein  
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Figure 4-3 Labeling of MBP-Intein-CBD bacterial lysate with Fluorescein-5-
Malimide. A) Coomassie stained SDS-PAGE gel of MBP E. coli lysate. B) 
Fluorescent image of  SDS-PAGE gel of MBP E. coli lysate after being reacted 
with Fluorescein-5-Maleimide. L denotes ladder. Lane 1 contains MESNA 
treated lysate as a positive cleavage control. Lane 2 is selenocysteine cleaved 
protein.  Images A & B are identical but not shown at the same scale.  
B A 
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clearly seen with a strong band at 41 kDa, and a very faint band at 72 kDa. Cleavage 
efficiency was calculated to be 95% by gel densitometry. In Lane 2 of Figure 4-3B, a 
strong fluorescent band is seen at 41 kDa indicating labeling of the MBP with 
maleimide-fluorescein through the Sec linker. A small degree of non-specific labeling 
is seen for other lysate proteins that may be degradation products or incomplete 
titration of cysteine groups. After removal of excess fluorescein by spin column, the 
labeling efficiency of fluorscein-5-maleimide to the cleaved MBP was calculated to be 
87%.  
 
Column Purification and Labeling of MBP-Intein-CBD: 
The MBP-intein-CBD fusion was purified from a chitin column using selenocysteine 
as both cleavage and linking agent. After packing, approximately 9 mg of MBP lysate 
was loaded on a 3 ml chitin affinity column via FPLC. A 3 CV wash was performed 
and the fraction was collected containing about 6 mg of total protein. Activated Sec 
was then used to cleave the MBP from the intein and elute it off the column yielding 
approximately 1.5 mg purified MBP, after which it was conjugated to maleimide-
fluorescein. Lane 1 of Figure 4-4 shows the fluorescent image of the Sec elution 
fraction. Not surprisingly, only the MBP band shows fluorescence in the purified 
fraction. Lane 2 of Figure 4-4 shows the fluorescent labeling of the wash fraction. 
Fluorescent labeling was achieved by adding Sec then fluorescein to the wash fraction 
to determine how much MBP was lost in the wash step. Significant MBP loss in the 
wash mostly occurred due to overloading the chitin beads and the relatively low pH of 
the wash buffer interfering the column‟s affinity. Lane 3 of Figure 4-4 shows the wash  
 102 
  
                         
d     L                 1                        2                 3  
Figure 4-4. Fluorescent image of affinity purified MBP-Sec with 
Fluorescein-5-Maleimide labeling. L denotes ladder. Lane 1 contains the 
Sec eluted fraction exposed to Fluorescein-5-Maleimide. Lane 2 contains 
the wash fraction which was exposed to Sec and fluorescein to determine 
protein loss. Lane 3 contains the wash fractions exposed to Fluorescein-5-
Maleimide without Sec. 
 
Figure 4. Labeling of MBP-Sec purified protein with Fluorescein-5-
Maleimide.  
 
Figure 4. Labeling of MBP-Sec purified protein with Fluorescein-5-
Maleimide.  
 
41 kD 
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fraction exposed to fluorescein without Sec. No labeling occurs, as expected, and 
demonstrates the Sec dependency of the labeling process.  
 
MBP Labeling of Maleimide-Gold Nanoparticles: 
 
 In order to demonstrate the system‟s compatibility with labeling nanoparticles and 
other surfaces, maleimide functionalized 0.8 nm nanoparticles were obtained 
commercially and labeled with MBP-Sec. Purified MBP-Sec was obtained from a 
chitin column as described and incubated with the maleimide labeled gold 
nanoparticles to form permanent, covalently linked conjugates. Samples containing 
MBP-Sec alone, nanoparticles alone, and MESNA eluted MBP  with particles at pH 5, 
and Sec eluted MBP and particles were prepared and individually spotted on activated 
nitrocellulose then aspirated off after hybridization, as seen in Figure 4-5A. As 
expected a yellow spot indicative of nanoparticles is observed in spots 2-4, all of 
which contained nanoparticles. Figure 4-5B illustrates the same nitrocellulose after a 
western blotting procedure with Anti-MBP-HRP. Spot 1 which contained the MBP 
only positive control blots positive, as expected. Spot 2 contained the particle only 
control and does not develop, as expected. Spot 3 which contained the Sec eluted 
MBP at pH 5 and maleimide particles developed positively, indicating successful 
conjugation to the nanoparticles. The fourth spot which contained MESNA eluted 
MBP at pH 5 did not develop. This is expected, as MESNA is not able to conjugate to 
the maleimide at pH 5 since its thiol is protonated. Unbound MBP is not seen in spot 4 
because of nanoparticle exclusion of the protein from the blot and the short  
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Figure 4-5. MBP Labeling of Maleimide-Gold Nanoparticles. Spots 1-4 
contain MBP, nanoparticles, nanoparticles and Sec eluted MBP at pH 5, and 
nanoparticles and MESNA eluted MBP at pH 5 respectively.  
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development time of the western blot since spots 1 and 3 contained large amount of 
MBP and developed almost instantly.    
 
While maleimide labeled particles were used to establish a permanently bonded MBP-
particle conjugate, selenide could also bond directly to 60 nm gold particles. The 
ability of selenide to bond to gold and silver is well established.
(23)
 The selenide bond 
is more stable and ~ 0.25 eV stronger than the corresponding thiol bond, though Se 
establishes lower surface coverage due to higher tilt angle of the conjugate.
(23)
  
 
Production of A33-ScFv-Intein in Pichia pastoris & Maleimide-Fluorescein Labeling 
for FACS 
 
MBP was used as a model to establish Sec as an intein cleavage and pH selective 
linking agent. After the system was developed, it was used to conjugate maleimide-
fluorescein to a humanized single chain antibody against the A33 cancer antigen 
(A33ScFv) 
(22)
 which was then used for fluorescence activated cell sorting. A synthetic 
DNA construct, codon optimized for Pichia pastoris, was produced containing the 
A33 single chain antibody fused in-frame to the Mxe intein and a 6x-His tag added to 
the C-terminus. The construct was sub-cloned into the P. pastoris expression vector 
pPiczA and transformed into the GS115 P. pastoris strain. While Pichia has been 
shown to secrete the A33 ScFv
(22)
 and many other recombinant proteins
(24, 25)
, the 
A33ScFv-Intein-His construct did not secrete. Expression was induced under a variety 
of temperatures and in GS115 strains containing foldases such as BIP and PDI
(26)
, but 
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the construct still did not secrete. Due to the lack of secretion, P. pastoris expressing 
the fusion protein intracellularly was lysed and the ScFv construct was purified by 
immobilized metal affinity chromatography, eluting one preparation with Sec by intein 
cleavage and a second with imidazole for use as an uncleaved control.       
 
 Figure 4-6 demonstrates successful fluorescein labeling of the ScFv construct by 
FACS. Figure 4-6A compares unlabeled SW1222 cells which bear the A33 cancer 
antigen, to a positive control containing SW1222 cells labeled by commercially 
available monoclonal antibody bound by a fluorescein labeled secondary antibody. 
Fifty-three percent of the cell population was labeled with the fluorescent control. The 
relatively low percentage of labeling is not surprising for SW1222 cells as they secrete 
a significant amount of extracellular matrix and tend to aggregate, inhibiting labeling. 
Figure 4-6B shows cell labeling by Sec cleaved A33 that was labeled with maleimide-
fluorescein. The fluorescently tagged ScFv labeled 49 percent of the SW1222 cell 
population (filled red block) as compared to unlabelled cells (unfilled black outine). 
This indicates the system was successful, as the ScFv had a labeling efficiency almost 
as high as the commercially available monoclonal antibody. Figure 4-6C demonstrates 
the Sec dependence of the labeling reaction. The uncleaved A33ScFv-Intein-His 
construct was eluted from the IMAC chromatography column using imidazole. It was 
then exposed to maleimide-fluorescein prior to labeling SW1222 cells. In this control 
only 11 percent of the cell population  
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A 
Figure 4-6. Fluorescence Activated Cell Sorting of SW1222 Cancer Cells labeled 
with Sec-Fluorescein-5-Maleimide functionalized A33 single chain antibody. 
Unfilled black outlines correspond to the unlabeled cell populations. The red, 
filled groups correspond to the labeled cell populations. A) Fluorescein labeled 
monoclonal Ab positive control B) Maleimide-fluorescein labeled ScFv C) ScFv 
exposed to maleimide-fluorescein without Sec. 
B 
C 
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was labeled positively as compared to the negative control. The 11% false positive 
labeling most likely stems from incomplete titration of cysteine residues present in the 
single chain.  
 
Conclusions: 
We have demonstrated a straightforward system for protein conjugation in a pH 
dependent, amino acid specific manner. We have shown the system‟s ability to 
selectively label proteins from lysate, elute and label a protein from an affinity column 
while cleaving the protein from the affinity tagged intein, and have demonstrated the 
system‟s ability to functionalize nanoparticles and maleimide labeled surfaces. 
Furthermore, we have demonstrated its ability to label a single chain antibody that was 
subsequently used for FACS. This system provides a direct means to label or 
conjugate proteins and introduces selenocysteine into the construct which is highly 
desirable for the chemical and biotechnological properties.  
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CHAPTER 5 
CONCLUSIONS & FUTURE DIRECTION S 
 
 
 
  
 114 
This body of work demonstrates the utilization of biochemistry, spectroscopy, 
and materials science to create better tools for SERS based investigation of biological 
systems. Specifically, a novel SERS biosensor for the detection of SNPs was 
developed, the binding kinetics and fluorescent quenching capacity of CTAB coated 
nanorods were investigated, and a novel protein functionalization system was created. 
These investigations complement each other because they researched key aspects of 
SERS based biosensors. The SNP sensor provided a new method of detection, the 
nanorod investigation provided information on nanorods useful as Raman enhancers, 
and the functionalization method is valuable for putting proteins on particles or 
surfaces for SERS experiments.  
The LDR-SERS methodology provided a new platform for SNP detection 
which could ultimately be used as a point-of-care methodology for in-office screening 
of SNP profiles. In the future, multiple elements of the platform could be further 
researched. Increasing the number of probes that can be multiplexed would be critical 
for clinical use. Although diagnostic peaks can be visually indentified now, as the 
number of Raman spectra is increased, the peaks will begin to overlap. To solve this, 
further research needs to be done to deconvolute the mixed signals through principal 
component analysis or support vector analysis. To make the purification process less 
labor intensive, a method for addition of the Raman enhancing nanoparticles prior to 
the LDR reaction should be developed. DNA structure may have to be modified to add 
a hairpin or other reactive element to allow room for the ligase to interact with the 
DNA but also keep the nanoparticle in close proximity to the fluorophore located on 
the second oligonucleotide. 
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 By investigating the fluorescence quenching and kinetic trafficking of CTAB 
coated nanorods, the study clarified how nanorods may be used as Raman enhancers. 
As previously mentioned, fluorescence quenching is important for SERS as a 
fluorescent signal can easily overwhelm a Raman signal. The ability of the nanorods 
to capture and hold non-polar molecules of interest is also critical to Raman detection 
of those substances. The study additionally showed that SPR could be used as a 
platform to model trafficking in a nanoparticle bilayer. In the future, several elements 
of this project could be further researched. It would be interesting to examine 
fluorescence quenching simultaneously with the SPR experiment. This is possible by 
measuring excitation and quenching optically above the chip while the light 
reflectance of the SPR is measured below the chip. This experiment could examine 
how a variety of variables interact, such as flow rate and concentration‟s affect on 
fluorescence quenching. Other interesting factors that could be investigated include 
how the aspect ratio of the rods or physiologically mimicking buffer conditions would 
affect trafficking behavior and quenching.  
 Development of the intein mediated, Sec dependent protein conjugation system 
could prove an excellent way to conjugate proteins to nanoparticles. The system 
allows easy, terminal conjugation of a protein to a selenocysteine residue in cell lysate 
or from a purification column. The selenocysteine residue then enables a variety of 
functionalization schemes to particles or surfaces through a reactive maleimide group 
or directly to the surface if it is gold or other noble metal. This project also has 
elements that could be further investigated. Direct conjugation of the selenocysteine to 
gold surfaces needs to be investigated and optimized, as it has not been empirically 
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tested yet in this system. Peptide ligation through the selenocysteine residue also needs 
to be tested and would add more utility to the system. Further optimization of the 
system could also be performed to find the minimum amount of selenocysteine 
required per mole of protein. The system currently uses excess Sec to help drive the 
reaction. Overall, each of these investigations contributes to an important component 
of SERS based biosensors and helps further scientists‟ ability to understand and utilize 
biological systems.  
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APPENDIX I 
EXPRESSION AND PURIFICATION OF CGMP GRADE NY-ESO-1 FOR 
CLINICAL TRIALS 
  
Adapted with permission from ―Expression and purification of cGMP grade 
NY-ESO-1 for clinical trials.‖ Lowe et. al. Biotech. Prog. 27(2). 435-441. 
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Abstract: 
NY-ESO-1 is a cancer testis antigen expressed in numerous cancers. Initial tests have 
shown its efficacy as a cancer vaccine, stimulating the body‟s own immune response 
against the invading tumor. In order to produce enough material for phase I clinical 
trials, a process using current Good Manufacturing Practices to produce clinical grade 
material was developed and executed. His-tagged NY-ESO-1 was expressed in 
C41DE3 Escherichia coli under control of the T-7 promoter. NY-ESO-1 was 
produced in a 20L fed-batch fermentation utilizing a pH-stat control scheme. The 
protein was then purified from inclusion bodies using a three-column process that 
achieved a yield of over 3.4 g and endotoxin below the detection limit of 0.005 EU/µg 
protein.   
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Introduction:  
     The NY-ESO-1 protein, also know as CTAG1 and LAGE-2, is a cancer testis (CT) 
antigen that holds significant promise as an immunotherapeutic vaccine. It was first 
identified by serological analysis of recombinant cDNA expression libraries (SEREX) 
from tumor mRNA and host serum. Its expression has been detected by RT-PCR and 
immunohistochemistry in multiple cancers, including melanoma 
1
, neuroblastoma 
2
, 
and soft tissue sarcoma.
3
 The gene is located in q28 region of the X chromosome and 
is a member of the CT-X antigen family.
4
 NY-ESO-1 is one of the most immunogenic 
CT-antigens, eliciting immunity spontaneously and after vaccine administration 
5
. 
Clinical responses were also detected in chemo-refractory cancers 
5
.  
     CT antigens make excellent vaccine candidates as their expression is limited to 
only cancerous cells and normal, testis germ cells 
6
. Testis germ cells are MHC class 1 
negative however 
7
 and will not elicit a cytotoxic response. To this end, NY-ESO-1 
vaccines supplemented with the ISCOMATRIX adjuvant have been successful in 
melanoma vaccine trials 
8
. NY-ESO-1 has also been shown to be a prognostic factor 
for malignant melanoma (MM). It was additionally demonstrated that MM expressing 
NY-ESO-1 was associated with thicker primary lesions, and had a higher frequency 
metastatic disease 
9
. NY-ESO-1 vaccines were shown to be even more successful 
when combined with an anti-CTLA-4 antibody treatment, as CTLA-4 has been shown 
to downregulate T-cell signaling and activity 
10
. Due to the protein‟s success in initial 
experiments, a critical need is growing for material used in limited phase-I clinical 
trials. Pilot-scale production of vaccine antigens, under current good manufacturing 
practices (cGMP), fills an important role where industrial scale production may not be 
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economically viable.  
      Here we have developed a process suitable for the pilot-scale production of cGMP 
grade His-tagged NY-ESO-1. Due to its extremely high hydrophobicity, the protein 
presented complex solubility and endotoxin removal challenges that were addressed 
during process development. After strain development, the process was scaled to a 2L 
fermentor using a fed-batch program and initial chromatographic development was 
conducted on the bench scale. Development and production was then moved into our 
cGMP-certified Biologics Production Facility.  
Materials and Methods: 
All materials were purchased at the highest purity possible and certificates of analysis 
from the manufacturer were retained. All equipment was cleaned and tested in 
accordance with cGMP guidelines. All of the staff was trained on and followed cGMP 
guidelines during production of the biopharmaceutical material. Water for injection 
grade water was used for all solutions (Hyclone Inc. Logan, UT). All chromatography 
was performed using an Akta Purifier (GE Healthcare, Piscataway, NJ) controlled by 
Unicorn software version 4.12 (GE Healthcare, Piscataway, NJ). All chromatography 
columns were packed in-house and validated for symmetry and plate count as directed 
by manufacturer. Protein and endotoxin concentrations were established using 
Bradford and Limulus Amebocyte Lysate assays respectively, as previously described 
11
. 
 
Plasmid & Strain Construction: 
The NY-ESO-1 sequence was obtained from the GenBank database (Gene 1485, 
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Genbank BC130362.1 ). A synthetic NY-ESO-1 gene was constructed via PCR. The 
overlapping oligonucleotides (Table 1) were assembled and subjected to two 
successive rounds of PCR amplification to generate a 579 bp fragment using Platinum 
Taq DNA Polymerase HF (Invitrogen Corp, Carlsbad, CA). In the first round, primers 
1-10 (Table 1) were combined and cycled 20 times. For the second round, a one-tenth 
volume of the first round PCR was added to the second round that contained primers 
11-12 and was cycled 30 times. The resulting fragment was then cloned into pCR2.1 
(Invitrogen Corp., Carlsbad, CA) and sequenced with four-fold coverage. After 
successful sequencing, the construct was subcloned into pET-9a24a, a derivative of 
the pET9a vector, with the repressor binding site and lacI gene removed. The 
construct was then transformed into C41(DE3) E. coli (Lucigen Corp., Middleton, WI) 
and positive clones selected by Kanamycin resistance. The pRARE plasmid, which 
encodes tRNAs rarely used in bacteria, was then transformed into the cells using 
Chloramphenicol as a marker. From a single positive clone, master and working cell 
banks were established. The banks were fully characterized by re-sequencing and 
performing diagnostic restriction digests of the plasmids, identifying the C41 E. coli 
species by 16S sequencing and IPTG tolerance phenotype, and western blot analysis 
of lysate using anti-NY-ESO-1 monoclonal antibody before and after expression of 
NY-ESO-1 was induced (data not shown).  
 
Fermentation: 
A 1 ml aliquot from the working cell bank was completely thawed at room 
temperature and added to 50 ml of production culture medium, as previously described  
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Number Oligonucelotide Sequence (5‟-3‟) 
1 CATATGCAAGCAGAAGGTCGTGGTACAGGTGGTTCTACGGGCGATGCTGATGGCCCAGGAGGT
CCAGGCATTCCAGAT 
2 AGGCGGGTGCAACTGGTGGCCGTGGTCCACGTGGTGCAGGAGCTGCTCGTGCATCAGGTCCAG
GAGGAGGAGCACCTC 
3 ATGGATGTTGTCGTTGTGGCGCACGTGGTCCGGAGAGCCGCCTGCTTGAGTTCTATCTTGCCA
TGCCTTTCGCGACTC 
4 GCACAGGATGCTCCACCGCTTCCGGTTCCTGGTGTGCTTCTGAAGGAGTTCACTGTGTCCGGC
AACATTCTGACTATC 
5 CACCGCCAACTGCAGCTCTCCATCAGTTCGTGTCTCCAGCAGCTTTCCCTGTTGATGTGGATC
ACGCAGTGCTTCCTG 
6 GACCACGGCCACCAGTTGCACCCGCCTCACCTGGACCACCTGCATTACCCCCTGGACCATCTG
GAATGCCTGGACCTC 
7 CGCCACAACGACAACATCCATTAAGACCAGAAGCTGCGCCACCATGTGGACCGCGAGGTGCTC
CTCCTCCTGGACCTG 
8 AAGCGGTGGAGCATCCTGTGCCAGACTACGGCGTGCCAGTTCAGCTTCCATTGGAGTCGCGAA
AGGCATGGCAAGATA 
9 ACGAACTGATGGAGAGCTGCAGTTGGCGGTGGTCTGCGGCGGTCAGTCGGATAGTCAGAATGT
TGCCGGACACAGTGA 
10 GCGGCCGCTTAACGGCGTTGCCCTGATGGAGGTTGAGCTAAAAACACAGGCAGGAAGCACTGC
GTGATCCACATCA 
11 CATATGCAAGCAGAAGGTCGTGGTACAGGTGGTTCTACG 
12 GCGGCCGCTTAACGGCGTTGCCCTGAT 
Table 1. Oligonucleotide Sequences for Gene Construction 
 123 
11
, in a sterile 250 ml flask. This was cultured overnight at 37°C and 250 rpm. The 
culture was then inoculated into 350 ml of production media in a sterile 2 L shake 
flask. Cells were grown for 2 hours at 37˚C, after which they were aseptically 
introduced into a 30L BioFlo 4500 Bioreactor (New Brunswick Scientific, New 
Brunswick, NJ) containing 7L of production media. The reactor was controlled and 
data was logged using AFS-Biocommand Bioproessing software version 2.6 (New 
Brunswick Scientific, New Brunswick, NJ). During fermentation, dissolved oxygen 
(DO) was maintained at 40% of saturation and was controlled by a DO cascade of 
agitation  (maximum of 1000 rpm) followed by supplementation with pure oxygen as 
needed. The temperature, pH, and gas flow were set to 37°C, 6.8, and 20 standard 
liters per minute respectively. pH was maintained during the batch phase of the 
fermentation with 5M NaOH. Upon consumption of the glucose in the batch phase, the 
base feed was turned off and 12.5 L of glucose feed containing IPTG was started, as 
previously formulated. 
11
.  Feed rate was controlled using a pH-stat feedback 
mechanism.  
Harvest, Lysis, and Inclusion Body Isolation: 
Fermentation culture was harvested into a sterile bioprocess bag, and then fed into a 
Carr Powerfuge Pilot (Pneumatic Scale Corp., Cuyahoga Falls, OH) spinning at 
maximum speed, from which the resulting cell pellet was collected. Approximately 
one half of the concentrated biomass was frozen at -20°C to be processed later in a 
manner identical to the first,  while the second half was resuspended in 15 L of lysis 
buffer containing 50 mM Tris Base, 100 mM NaCl, 1 mM MgSO4, 1 mM ß-
mercaptoethanol, 1 ml “Turbo” DNase (Ambion, Inc., Austin, TX) at pH 8.0. Portions 
 124 
of the cell suspension were sequentially blended in a 4 L Waring laboratory blender 
and transferred to a clean, sterile bioprocess bag. The disrupted cells were then passed 
through a Microfluidics Microfluidizer M100EH (Microfluidics International Corp., 
Newton, MA) at 23 Kpsi three times. The lysate was then pumped into a Millipore M-
30 tangential flow filtration (TFF) (Billerica, MA) system equipped with two, 0.2 µm 
Centrasette II cassettes (Pall Corp., Port Washington, NY). Diafiltration was then 
performed on the lysate, first washing with 50 L of Tris buffer (50 mM Tris Base, 100 
mM NaCl, 1 mM Na2EDTA • 2H2O, 1 mM ß-mercaptoethanol at pH 8) then 50 L of 
phosphate buffer (50 mM phosphate, 500 mM NaCl, 1 mM ß-mercaptoethanol at pH 
7.5). The inclusion body suspension was then concentrated 10-fold.  
Solubilization and Filtration: 
Processed inclusion bodies were solubilized for 16 hours while being mixed by an 
overhead mixer in 35 L of solubilization buffer [2% m/v deoxycholate (sodium salt), 
8M urea, 50 mM phosphate, 200 mM NaCl, 100 mM KCl, 10 mM imidazole, 2.5 mM 
ß-mercaptoethanol at pH 7.5]. The solution was then passed through a 10” 1.2 µm low 
protein binding filter (LPBF) and subsequently a 10” 0.5 µm LPBF.  
Immobilized Metal Affinity Chromatography & Buffer Exchange: 
The filtered lysate was loaded at 100 mL/min onto a 5 L column containing nickel-
bound Chelating Sepharose Fast Flow resin (GE Healthcare, Piscataway, NJ), 
previously equilibrated with two column volumes (CVs) of solubilization buffer. Each 
chromatography fraction was collected into sterile bioprocess bags. The program had 
the following design: 2 CV load, 7 CV solubilization buffer wash, 5 CV urea buffer 
(4M urea, 50 mM phosphate, 2.5 mM ß-mercaptoethanol at pH 7.5) wash, 5 CV 15% 
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imidazole buffer (formulated as urea buffer with 500 mM imidazole) diluted into urea 
buffer, and 3 CV elution with 100% imidazole buffer (1 M imidazole). The elution 
fraction was concentrated to 1 L using a Millipore ProFlux M12 TFF system with two 
10 KDa Centramate cassettes (Pall). The retentate was then exchanged with 5 L of 
urea buffer and collected into a sterile bioprocess bag. 
Anion Exchange Chromatography: 
The buffer exchanged retentate was loaded at 50 ml/min onto a 1 L column containing 
Q Sepharose XL resin (GE Healthcare, Piscataway, NJ) at 50 ml/min. The purification 
program had the following design: 2 CV equilibration with urea buffer, 1 CV load, 
and 2 CV urea buffer wash/elution. The load flowthrough and wash were collected as 
one fraction in a sterile 10 L bioprocess bag.  
Hydrophobic Interaction Chromatography: 
The AXC flowthrough/wash fraction was diluted to a protein concentration of 0.4 
mg/ml using urea buffer, and subsequently diluted with ammonium sulfate buffer (4 M 
urea, 50 mM sodium phosphate, 2 M ammonium sulfate, 2.5 mM ß-mercaptoethanol) 
such that the final concentration of ammonium sulfate was 0.7 M. This was loaded at 
50 ml/min onto 1 L column containing Phenyl HP (GE Healthcare, Piscataway, NJ) 
resin that had been pre-equilibrated with urea buffer supplemented with 0.7 M 
ammonium sulfate.  After loading, the column was washed with equilibration buffer 
for 2 CVs. The protein of interest was then eluted in three fractions using a HIC 
elution buffer [4M urea, 0.5% Triton (v/v), 50 mM sodium phosphate, and 2.5 mM ß-
mercaptoethanol at pH 7.5]. Fractionation was controlled using the Unicorn software 
manually, based on 280 nm absorbance.  
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Final Buffer Exchange and Terminal filtration:  
The fractions eluted off the HIC column were concentrated to 1 L as described above 
in an M-12 TFF system and then buffer exchanged with 6 L of final bulk buffer (4M 
urea, 50 mM phosphate, 145 mM NaCl, 50 mM glycine). The product was then passed 
through a sterile 0.22 µm disc filter (Millipore, catalog number MPGL06GF2) under 
sterile conditions into a bioprocess bag.  
Results and Discussion: 
Plasmid and Cell Bank Construction: 
In order to improve expression of NY-ESO-1, a synthetic gene was constructed. This 
lowered the GC percentage from 67.4% to 56%, allowed for E. coli codon 
optimization, and minimized potential for stem-loop structures. This final construct 
was cloned into pET9a24a  (Figure 1). Due to the deletion of lacI and the repressor-
binding site, higher expression levels were achieved as compared to the stock 
plasmids.  The C41 strain of E. coli cells was chosen due to its strong growth during 
batch and fed-batch (induction) phases, high levels of target protein expression and its 
historic ability to produce membrane proteins 
12-15
. This allowed IPTG to be included 
in the glucose feed during the fermentation, which made the fermentation more 
streamlined and achieved high cell mass while achieving high protein yield. C41(DE3) 
cells, which are derived from BL21(DE3)
16
, have at least one uncharacterized 
mutation which allows them  to produce these normally toxic proteins.  
Fermentation: 
The fermentation profile of cells expressing NY-ESO-1 is shown in Figure 2. The 
fermentor was prepared, DO probe allowed to polarize, and then inoculated at  
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Feature Description Location Purpose 
CDS His SNY 176-754 His tagged 
synthetic NY-
ESO-1 
 KN(R) 3719-
4531 
Kanamycin 
resistance gene 
PBS T7 
Terminator 
68-86 Primer binding 
site 
 T7 
Promoter 
811-830 Primer binding 
site 
PRO T7 P 814-830 Expression 
promoter 
RBS RBS 760-765 Ribosomal 
binding site 
ORI pBR322 
ORI 
2977-
3620 
Origin of 
replication 
 F1 ORI 4626-
5081 
Origin of 
replication 
TERM T7 TERM 25-71 Transcription 
terminator 
 
MRGSHHHHHH GSMQAEGRGT GGSTGDADGP GGPGIPDGPG GNAGGPGEAG 
ATGGRGPRGA  GAARASGPGG GAPRGPHGGA ASGLNGCCRC GARGPESRLL 
EFYLAMPFAT PMEAELARRS LAQDAPPLPV PGVLLKEFTV SGNILTIRLT 
AADHRQLQLS ISSCLQQLSL LMWITQCFLP VFLAQPPSGQ RR *** 
 
 
Figure 1. Top Panes – NY-ESO-1 in pET9a24a plasmid map and key. Bottom 
Pane- Amino Acid Sequence of NY-ESO-1. Asterisks indicate an ochre stop 
codon.   
 128 
  
 
Figure 2. Fermentation profile of NY-ESO-1. Dissolved oxygen (black) 
and glucose feed (blue) measurements. A pH-stat control method was used  
to determine feed rate. 
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approximately 1150 minutes. In Figure 2, a sharp drop in DO is noticeable at 
approximately 1300 minutes, indicating the beginning of glucose consumption in the 
batch phase. Shortly thereafter, a DO spike indicated exhaustion of glucose. The 
software turned on the glucose feed, and the DO returned to the target DO of 40% of 
air saturation. As total biomass mass increased, DO was maintained by an increase in 
agitation and supplementation of pure oxygen. Figure 2 shows the rapid increase in 
feed rate to compensate for cell growth. Feeding rate was controlled by a pH feedback 
loop. In this strategy, available glucose is kept at a minimum and feeding rate is only 
affected by pH 
17
. As bacteria grow, they acidify the media, thus pH can be used as a 
measure of growth. Approximately twenty-four hours after inoculation, the cells were 
harvested, achieving a cell density of 232.7 g/L wet cell weight.  
Purification: 
After harvest, the cells were lysed to obtain inclusion bodies, which were subsequently 
washed with by diafiltration. Tris and phosphate buffer washes differentially removed 
a significant amount of contaminating host proteins as seen in Figure 3, lanes 3-5. 
After concentration, solubilization in 8M urea, and filtration through 1.2 and 0.5 µm 
filters, the lysate was loaded onto a 5L nickel-charged IMAC column.  The 
chromatogram in Figure 4 presents the purification of NY-ESO-1 on the IMAC 
column. After loading (Figure 4A1), the bound protein was washed with a 
deoxycholate/Triton-114 solution (Figure 4A2) to remove lipopolysaccharides 
(endotoxin) bound to the protein. During development, it was found that NY-ESO-1 
strongly bound endotoxin, as do many other CT-Antigens 
18
.  This multi-detergent 
wash is key to drastically reducing endotoxin levels in the protein preparation.  
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Figure 3. A: Coomassie-stained SDS-PAGE gel of TFF and 
IMAC column. Lanes 1–10 correspond to: ladder, NY-ESO-1 standard, 
crude lysate, Tris wash permeate, phosphate wash permeate, 
concentration permeate, TFF retentate, cassette wash retentate, and 
concentration retentate. Arrow corresponds to NY-ESO-1 
monomer 
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Figure 4. A: Chromatogram of IMAC column. Fractions 1–5 correspond to: 
load, deoxycholate wash, urea wash, low-imidazole wash, elution. B: 
Coomassie-stained SDS-PAGE gel of IMAC column fractions. Lanes 1–10 
correspond to: ladder, NY-ESO-1 standard, load, load FT, deoxycholate wash, 
low-imidazole wash, early high-imidazole elution, mid-high-imidazole elution, 
late high-imidazole elution, and blank. Arrow indicates NY-ESO-1 monomer 
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Subsequent column steps are able to reduce endotoxin to below detectable limits, as 
seen in Table 2. The detergent wash step is additionally important because it removes 
latent endotoxin that later dissociates from NY-ESO-1. A previous batch of NY-ESO-
1 that did not originally include a detergent wash step was measured at less than 0.1 
EU/µg, and over a fourteen month period rose to 0.6 EU/µg. Another batch behaved 
similarly, rising from 0.27 EU/µg to 1.6 EU/µg over ten months. Batches made using 
the process described here have maintained undetectable levels of endotoxin for a year 
at the time of this article.  
     Figure 4A3 shows that the urea wash is able to remove the detergent from the 
protein preparation, as seen from the drop in 280 nm absorbance. Figure 4A4 and 4A5 
shows the low imidazole wash and high imidazole elution. Figure 4B illustrates the 
purification resulting from the IMAC column step. Although some NY-ESO-1 is lost 
in the load flow-through (FT), as seen in Figure 4B lane 4, most host proteins pass 
through the IMAC column.  A single band is seen in the deoxycholate wash and low 
Imidazole wash lanes, but does not react on an anti-NY-ESO-1 western blot (data not 
shown). Figure 4B lanes 7-9 show consistent elution of NY-ESO-1 throughout the 
elution step. The upper band eluted does appear in an anti-NY-ESO-1 western blot. 
Note the slightly lower molecular weight as compared to the band appearing in the 
deoxycholate wash lane. The eluted protein was then buffer exchanged into an AXC 
buffer with a seven percent loss of total protein mass. 
     Anion exchange chromatography was performed following the IMAC column, as 
an initial polishing step (Figure 5). The chromatogram of the process can be seen in 
Figure 5A. In addition, contaminants such as host proteins and endotoxin, with a  
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Sample Endotoxin 
Concentration 
(EU/ml) 
IMAC Load 4913800 
QXL Load 316.1 
QXLElution 10.9 
HIC Load < 5 
HIC Elution < 5 
Final Bulk < 5 
Table 2. Endotoxin Concentration During Processing 
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Figure 5. A: Anion exchange column chromatograph and B: HIC 
chromatograph. Elution fractions indicated by dotted lines and numbers 
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higher binding affinity to the anion exchange matrix under these conditions, remained 
bound. No decrease in NY-ESO-1 yield was observed as seen in Figure 6, lanes 3 and 
4. The AXC flow through was then diluted and supplemented with 0.7 M ammonium 
sulfate in preparation for the HIC column.  
     Hydrophobic interaction chromatography was used as the third and final polishing 
step for NY-ESO-1 purification (Figure 5B).  After protein loading and urea buffer 
wash, NY-ESO-1 was eluted in three fractions with a 0.1% (v/v) Trition-114 solution 
in aqueous 4M urea, as seen in Figure 5B. No conditions were changed during the 
elution, but three distinct fractions are obtained. The protein profile in each of these 
fractions was identical despite the higher protein concentration in fraction 1 (Figure 6, 
lanes 8-10).  As a result of its hydrophobic nature, elution of NY-ESO-1 from the HIC 
column required formulation of the elution buffer with Triton-114.The elution pattern 
of the protein is believed to have occurred because of an interaction between the 
detergent and the hydrophobic resin. The initial spike in absorbance seen in fraction 1 
occurred as expected, when the presence of detergent in the elution buffer assisted in 
release of a majority of protein. As the elution step continued, NY-ESO-1 could still 
be detected in fraction 2 and a slow rise in absorbance was observed. We believe 
detergent buildup on the hydrophobic column released in fraction 3. The sharp rise in 
280 nm absorbance was associated with the strong UV absorbance of Triton-114. The 
fraction collection was ended prior to the plateau of the peak where a majority of the 
Triton was found. No protein was detected in the plateau portion of the chromatogram. 
Previous experiments showed the importance of cutting the peak prior to the plateau, 
as it greatly reduces Triton-114 contamination in the protein preparation.  
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Figure 6. Coomassie-stained SDS-PAGE gel of AXC and HIC 
fractions. Lanes 1–10 correspond to ladder, NY-ESO-1 
standard, AXC load, AXC FT, prefiltered HIC load, HIC 
load, HIC FT, HIC fraction 1, HIC fraction 2, and HIC 
fraction 3. Arrow indicates NY-ESO-1 monomer. 
 
 
 137 
 
     The three HIC elution fractions were pooled then buffer exchanged into the final 
bulk buffer and terminally filtered under sterile conditions. Confirmation of detergent 
removal was achieved by HPLC (data not show). A summary SDS-PAGE and western 
blot using anti-NY-ESO-1 can be seen in Figure 7A&B respectively. Figure 7A shows 
that most of the protein purification occurs at the IMAC step, as would be expected. 
Some higher molecular weight proteins remain throughout the purification process. 
The higher molecular weight bands have been determined by mass spectrometry to be 
NY-ESO-1 bound to chaperone proteins such as DNA J, DNA K, and GroEL, as well 
as multimers of NY-ESO-1 (data not shown). The presence of NY-ESO-1 in these 
higher molecular bands was also confirmed by anti-NY-ESO-1 western blot (Figure 
7B). Release of NY-ESO-1 from the chaperone proteins was extensively investigated, 
but could not be achieved, despite methods such as reducing agents, chromatography, 
and altering the salt compositions and concentrations in buffers.  
  
 138 
  
Figure 7. A: Coomassie stained summary SDS-PAGE gel. B: Anti-NY-ESO-1 
Western blot of summary gel. Lanes 1–12 for A and B correspond to: ladder, 
NY-ESO-1 standard, crude lysate, TFF retentate, IMAC load, IMAC elution, 
QXL load, QXL elution, HIC load, HIC-pooled elution, prefiltered final bulk, 
and filtered final bulk. Arrow indicates NY-ESO-1 monomer 
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Conclusions: 
      This protein typifies CT antigens in that it was challenging to produce at the pilot 
scale under GMP conditions. Due to its hydrophobic nature, which leads to extremely 
low solubility in aqueous solution, NY-ESO-1 requires 8M urea during initial stages 
of purification and 4M urea once it has been eluted from the IMAC column. NY-ESO-
1 strongly binds endotoxin and requires a multi-detergent wash to remove the majority 
of this contaminant before polishing on secondary chromatography columns. Despite 
these challenges however, we were able to produce over 3 g of GMP grade NY-ESO-1 
from a single 20 L fermentation.  Most importantly, this material will enter limited 
phase-1 clinical trials where it is anticipated it will save patients’ lives.  
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APPENDIX II 
PROCESS DEVELOPMENT AND PRODUCTION OF CGMP GRADE MELAN-A 
FOR CANCER VACCINE CLINICAL TRIALS 
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Abstract: 
 
Melan-A is a cancer testis antigen commonly found in melanoma, and has been shown 
to stimulate the body‟s immune response against cancerous cells. We have developed 
and executed a process utilizing current good manufacturing practices (cGMP) to 
produce the 6x-His tagged protein for use in Phase I clinical trials in C41DE3 
Escherichia coli. Half of a 20 L fed-batch fermentation produced over 5.5 grams of 
purified Melan-A with less than 0.005 EU/ml endotoxin levels. Purification was 
achieved through a three column process utilizing immobilized metal affinity, anion 
exchange, and cation exchange chromatography with a buffer system optimized for 
low-solubility, high LPS binding capacity proteins.  
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Introduction: 
 
     The Melan-A protein, also known as MART-1, has been used as a diagnostic 
marker[1] for melanoma as well as an immunotherapeutic agent.[2] The tumor 
associated antigen (TAA) contains 118 amino acids, with 21 amino acids predicted to 
compose a transmembrane domain and 92 solvent exposed.[3] Melan-A was originally 
cloned by the Ludwig Institute for Cancer Research
[4] 
and was independently cloned 
by the NIH who termed it MART-1 (Melanoma Antigen Recognized by T-cells)[5]. 
The protein is expressed only in melanocytes, the retina, and most melanoma cancers. 
While it is expressed in virtually all metastatic melanomas, some primary, cutaneous 
melanomas have stained Melan-A negative.  
     Melan-A is a member of the MAGE gene family,
[6]
 which includes many TAAs  
that are recognized by cytotoxic T lymphocytes (CTL). Once recognized, CTLs lyse 
the cancerous cell.
[7]
  NY-ESO-1
[8]
  and SSX-2
[9]
 are two related TAAs which provoke 
similar reactions from CTLs and have had some success as cancer vaccines.  
Interestingly, it has been demonstrated that HLA phenotype strongly influences the 
efficacy of Melan-A vaccination due to the ability of the HLA molecule to present the 
antigen.
[10]
 Other TAAs appear to be antigenic when displayed by multiple HLA 
phenotypes.
[5, 11]
  
     Melan-A peptides have been delivered through viral vectors and directly as peptide 
solutions for use as cancer vaccine antigens. Virally, Melan-A has been expressed 
using lentiviral
[12]
, adenoviral
[13]
, and poxviral
[14, 15]
 vector systems. The studies‟ 
results strongly supported the use of Melan-A as an immunotherapy. This is especially 
 147 
well supported by the phase I/II clinical trials using inactivated vaccinia virus. 
Individuals have also been vaccinated with Melan-A peptides intravenously as part of 
clinical trials. In order to elicit a stronger CTL response, adjutants
[16]
 and combination 
therapies have been used. There has been significant evidence that masking the 
CTLA-4 protein on helper T-cells can significantly increase the immune response to 
vaccine antigens.
[17-19]
 As with any selective agent, resistance to CTLs has been 
observed
[20]
 and is further evidence that combination therapies are required for these 
vaccine treatments.  
     We have developed and successfully conducted a process to produce His-tagged 
cGMP grade Melan-A at the pilot-scale for clinical trials. The process utilizes a 20 L 
fed-batch fermentation and a three column purification scheme to remove 
contaminating proteins and endotoxin. With the protein‟s initial successes, a demand 
has grown for clinical grade protein that exceeds lab scale but is not economically 
viable for industrial scale. Here will fill the gap between laboratory and industry scale 
to provide Melan-A for use in vaccine clinical trials under a variety of conditions.  
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Materials and Methods: 
Materials: 
All materials used were obtained at the highest purity level possible.  All equipment 
was cleaned and tested in accordance with cGMP guidelines. Production staff 
followed strict cGMP training and operating procedures during production of the 
biopharmaceutical material. Water for injection grade water was used for all solutions 
(Hyclone Inc. Logan, UT). All chromatography was performed using an Akta Purifier 
(GE Healthcare, Piscataway, NJ) controlled by Unicorn software version 4.12 (GE 
Healthcare, Piscataway, NJ). Our production technicians packed all chromatography 
columns.  The columns were then checked for symmetry and plate count as directed 
by the manufacturer. Protein and endotoxin concentrations were established using 
Bradford and Limulus Amebocyte Lysate assays respectively, as previously 
described.
[21]
 
 
Plasmid & Strain Development: 
The Melan-A gene sequence as deposited into Genbank (Accession Number 
NM_005511.1 was synthesized by IDT (Coralville, IA), with a 6x His tag added to the 
C-terminus to assist in purification. During gene synthesis, IDT performed codon 
optimization for E. coli for optimal recombinant expression, The Melan-A expression 
plasmid was constructed by sub-cloning the synthesized gene into the pET9a24a 
expression vector.
[8]
  The constructed plasmid was sequenced with four fold 
redundancy using the forward primer 5‟-taatacgactcactataggg and reverse primer 5‟-
caaaaaacccctcaagacccgttta. From a single positive clone, master and working cell 
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banks were established using the C41DE3 E. coli strain. Banks were subjected to 
extensive identity and expression testing as previously described.
[8]
 
 
Methods: 
Fermentation: 
     A vial from the working cell bank was used to inoculate 50 ml of production 
culture medium, as previously described
[21]
, in a sterile 250 ml flask. The culture was 
shaken at 250 RPM overnight at 37˚C. The entire culture volume was then aseptically 
inoculated into 350 ml of production media in a sterile 2 L shake flask. Cells were 
shaken at 37˚C for two hours, after which they were aseptically inoculated into a 25L 
BioFlo 4500 Bioreactor (New Brunswick Scientific, New Brunswick, NJ) containing 
7L of production media. AFS-Biocommand Bioproessing software version 2.6 (New 
Brunswick Scientific, New Brunswick, NJ) controlled the fermentation and logged all 
reaction conditions. During fermentation, dissolved oxygen (DO) was maintained at 
40% of saturation and was controlled by a DO cascade of agitation  (maximum of 
1000 rpm) followed by supplementation with pure oxygen as needed. The 
temperature, pH, and gas flow were set to 37°C, 6.8, and 20 standard liters per minute 
respectively. 5M NaOH controlled the reactor pH during the batch phase. Upon 
exhaustion of the glucose in the batch phase, the base feed was turned off and 12.5 L 
of glucose feed containing IPTG was initiated, as previously formulated. [21] A pH-
stat feedback mechanism regulated the feed rate.  
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Buffer Composition: 
Lysis buffer: 50 mM Tris Base, 100 mM NaCl, 1 mM MgSO4, 1 mM ß-
mercaptoethanol, 2.5x10
-3 % (v/v) “Turbo” DNase (Ambion, Inc., Austin, TX) at pH 
8.0. Solubilization buffer: 2% m/v deoxycholate (sodium salt), 1% v/v Triton-114, 
8M urea, 50 mM phosphate, 200 mM NaCl, 100 mM KCl, 10 mM imidazole, 2.5 mM 
ß-mercaptoethanol at pH 7.5. Urea buffer: 4M urea, 50 mM phosphate, 2.5 mM ß-
mercaptoethanol at pH 7.5. Imidazole buffer: Formulated as urea buffer with 500 
mM imidazole. Carbonate buffer: 4M urea, 10 mM Carbonate, 1 mM 2-
Mercaptoethanol at pH 10.5 Carbonate elution buffer: Formulated as carbonate 
buffer with 1M sodium chloride at pH 10.5 Final Bulk Buffer: 4M urea, 50 mM 
phosphate, 145 mM NaCl, 50 mM glycine at pH 6.5 
 
Harvest & Lysis: 
The fermentate was harvested into a sterile bioprocess bag, and then fed into a Carr 
Powerfuge Pilot (Pneumatic Scale Corp., Cuyahoga Falls, OH) spinning at 18500 
RPM, from which the resulting cell pellet was collected. Approximately one half of 
the concentrated biomass was frozen at -20°C to be processed later in a manner 
identical to the first, while the second half was resuspended in 15 L of lysis buffer. 
Portions of the cell suspension were sequentially disrupted in a 4 L Waring laboratory 
blender and transferred to a clean, sterile bioprocess bag. The disrupted cells were 
subjected to three passes through a Microfluidics Microfluidizer M100EH 
(Microfluidics International Corp., Newton, MA) at 23 Kpsi.  
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Solubilization and Filtration: 
The lysate was solubilized for 18 hours while mixing via large stir-bar in 35 L of 
solubilization buffer. The solution was then passed through a 10” 1.2 µm low protein 
binding filter (LPBF) (Millipore Corp., Billerica, MA) and subsequently a 10” 0.5 µm 
LPBF (Millipore Corp., Billerica, MA).  
 
Immobilized Metal Affinity Chromatography & Buffer Exchange: 
All chromatography and mixing was done using a Akta Purifier FPLC (GE 
Healthcare, Piscataway, NJ) controlled by Unicorn software (GE Healthcare, 
Piscataway, NJ). The filtered lysate was loaded at 100 mL/min onto a 5 L column 
containing nickel-bound Chelating Sepharose Fast Flow resin (GE Healthcare, 
Piscataway, NJ), previously equilibrated with two column volumes (CVs) of 
solubilization buffer. Each chromatography fraction was collected into sterile 
bioprocess bags. The purification program used the scheme: 11 CV load, 7 CV 
solubilization buffer wash, 5 CV urea buffer wash, 5 CV 15% imidazole buffer diluted 
into urea buffer, and 3 CV elution with 100% imidazole buffer. The elution fraction 
was concentrated to 1 L using a Millipore ProFlux M12 TFF system with two 4 KDa 
Centramate cassettes (Pall). The retentate was then exchanged five-fold volumetrically 
with carbonate buffer and collected into a sterile bioprocess bag. The M12 system was 
run at 25% pump speed producing an inlet pressure of 30 PSI and outlet pressure of 20 
PSI for both the concentration step and diafiltration step.  
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Anion Exchange Chromatography: 
A 1 L column containing Q Sepharose XL resin (GE Healthcare, Piscataway, NJ) was 
equilibrated for 3 CVs at 50 ml/min with carbonate buffer. The retentate was then 
loaded with carbonate buffer at a 70:30 ratio at 50 ml/min for 3.8 CVs. The protein 
was then washed with 2.5 CVs of carbonate buffer and subsequently eluted with 5 
CVs of carbonate elution buffer. Each fraction was collected in a separate, sterile 
bioprocess bag.  
 
Cation Exchange Chromatography: 
The cation exchange column was conducted as a flow through column using 50 
ml/min as a constant flow rate. The column was equilibrated with 2 CVs carbonate 
elution buffer then was loaded with the anion exchange eluate for approximately 5 
CV. The column was then washed out with 1.5 CVs of carbonate elution buffer. The 
load flow-through and the wash out fractions were collected into a single, sterile 
bioprocess bag.   
 
Final Buffer Exchange and Terminal filtration:  
The fraction collected from the cation exchange column was concentrated to 1 L as 
described above in an M-12 TFF system and then buffer exchanged with 6 L of final 
bulk buffer. The protein solution was then passed through a sterile 0.22 µm disc filter 
(Millipore, catalog number MPGL06GF2) under sterile conditions into a bioprocess 
bag for storage.  
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Results and Discussion: 
 
Plasmid and Cell bank Construction 
     A synthetic version of Melan-A was developed to improve its production and 
purification. The genetic sequence was codon optimized for E. coli to avoid stringent 
responses from amino acid starvation due to codon bias [22]. The synthetic Melan-A 
sequence was further modified with a 6x-polyhistidine tag on the C terminus for 
purification. This version of Melan-A (Syn-Melan-A) has 375 base pairs encoding 124 
amino acids with a mass weight of 14.1 kDa.  The expression plasmid was constructed 
from the Syn-Melan-A insert and the pET9a24a plasmid (Figure 1). The C41 strain of 
E. coli was used as the host strain for its ability to produce high levels of membrane-
derived recombinant proteins.
[23]
        
 
Fermentation 
     The fed-batch fermentation was conducted under pH control using a feedback 
control loop. The DO, pH, glucose feed volume, base feed volume, and oxygen flow 
rate were all recorded during vessel preparation and post-inoculation. The vessel was 
inoculated at hour 21 of the fermentation. The batch phase is marked by acidification 
of the medium by the cells triggering addition of a proportionally controlled amount of 
sodium hydroxide into the vessel to maintain pH at 6.8. After approximately 30 ml of 
base was added to the vessel, the glucose feed loop was initiated but base was not 
added until the pH of the media increased above the set point.  As shown in Figure 2, 
the dissolved oxygen concentration (DO) begins to plummet at 22 hours into the  
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C 
 
 
Feature Description Location Purpose 
CDS Melan-A 203-577 His tagged synthetic Melan-A 
 KN(R) 3546-4358 Kanamycin resistance gene 
PBS T7 Terminator 68-86 Primer binding site 
 T7 Promoter 638-657 Primer binding site 
PRO T7 P 841-657 Expression promoter 
RBS RBS 587-592 Ribosomal binding site 
ORI pBR322 ORI 2804-3447 Origin of replication 
 F1 ORI 4453-4908 Origin of replication 
TERM T7 TERM 25-71 Transcription terminator 
    
 Mpredahfiygypkkghghsyttaeeaagigiltvilgvllligcwycrrrngyralmdkslhvgtq
caltrrcpqegfdhrdskvslqekncepvvpnappayeklsaeqspppysphhhhhh*** 
 
Asterisks denote opal stop codon (tga). 
 
Figure 1: A) pET9a24a plasmid map containing Syn-Melan-A. B) Plasmid 
map key highlighting purification, antibiotic resistance, and expression 
control features. C) Amino acid sequence. 
A 
B 
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Figure 2: Fermentation profile for Melan-A. Dissolved oxygen concentration 
(black) follows the profile seen for pH stat control. Glucose feed (blue) 
increases exponentially at the conclusion of the batch phase of the fermentation 
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fermentation indicating consumption of glucose by the cells.  DO concentration spiked 
26 hours into the fermentation indicating an exhaustion of the carbon source in the 
media. The pH of the media changed due to an accumulation of ammonium ions after 
the depletion of the primary carbon source 
[24, 25]
. This rise in pH triggered the addition 
of feed and was used to control the feed rate into the vessel. The glucose feed, 
containing IPTG, was introduced into the vessel at an exponential rate allowing for a 
constant growth rate during the induction process. The DO was maintained at 40% 
during the feed stage. The cells were deemed ready to harvest once the addition of 
feed did not cause an appreciable increase in the oxygen consumption rate. 
Fermentation completion reproducibly occurs 23 hours after inoculation.   
 
Purification 
     The cells were pelleted and lysed immediately after harvest to obtain inclusion 
bodies containing Melan-A. The lysate was solubilized in phosphate buffer containing 
8M urea, 1% Triton-114 and 2% w/v deoxycholate for 16 hours. The solubilized 
inclusion bodies were then filtered through a 1.2 µm and 0.5 µm low-protein binding 
capsule filter and loaded onto a 5L nickel column. Immobilized metal affinity 
chromatography (IMAC) was used as the initial purification column for Melan-A. The 
chromatogram in Figure 3A shows the results for the IMAC purification. Following a 
protocol developed previously by our group 
[8],
 the solubilized lysate was loaded onto 
the column (Figure 3AI) and subsequently washed with a solution of 8M urea, 2% w/v 
deoxycholate, and 1.0% v/v Triton X-114 (figure 3AII) to remove a significant 
amount of the endotoxin that is associated with the CT antigen. As described in our  
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Figure 3: A) Immobilized metal affinity chromatography (IMAC) column 
chromatogram for Melan-A. Sections I-V correspond to load, deoxycholate 
wash, urea wash, low imidazole, and high imidazole respectively.  B) 
Coomassie stained SDS-PAGE gel. Lanes 1-10 correspond to protein ladder, 
crude lysate, sample buffer (blank), filtrate (IMAC load), deoxycholate wash 
flow through, sample buffer (blank), IMAC load flow through, IMAC low 
imidazole, sample buffer (blank), and IMAC high imidazole. The red arrow 
indicates the Melan-A monomer band at 14 kDa. 
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previous reports, we determined that many CT-antigens bind the lipopolysacchrides 
produced by E. coli to high concentrations 
[8, 26]
. For example, the CT-antigen NY-
ESO-1 had endotoxin levels at 1,362.95 EU/µg prior to loading onto the IMAC 
column. Additionally NY-ESO-1 had latent endotoxin which gradually diffused out 
during storage if a detergent wash step was not included in the IMAC purification.
[8]
  
Melan-A solubilized inclusion bodies were found not to have as high of an endotoxin 
concentration as NY-ESO-1 (143.0 EU/µg in IMAC load). Even at these 
concentrations, the detergent wash step on the IMAC is essential to reduce endotoxin 
before the downstream columns. Table 1 details the endotoxin levels measured at 
several points in the purification process. Endotoxin was reduced to 0.00049 EU/µg in 
the IMAC High Imidazole elution. The majority of the endotoxin eluted with the host 
proteins in the load flow through (319.9 EU/µg) and in the deoxycholate wash step 
(15,000 EU/ml). Excess detergent was washed off of the column during the urea wash 
step. The detergents used in the previous step have a high 280 nm absorbance which 
plummeted after 1.5 column volumes of urea wash. A small amount of endotoxin is 
removed in this step with only a slight loss of protein (Table 1). Figure 3AIV-V shows 
the low and high imidazole fractions respectively. The quality of the IMAC 
purification was analyzed by Coomassie gel and Western blot. As shown in figure 3B, 
a large portion of the host proteins elute in the load flow through (lane 7). The 
deoxycholate wash removes a small fraction of target protein but as mentioned earlier 
it also removes a majority of the bound endotoxin (see Table 1).  A faint 14 kDa band 
corresponding to the Melan-A monomer is seen in the low imidazole fraction 
indicating some loss of product during this step. Most of the product, however, elutes  
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Sample 
Protein 
Concentration  
(mg/ml) 
Volume 
(ml) 
Total 
Protein (g) 
Endotoxin 
Concentration 
(EU/µg) 
IMAC Load 11.4 42000 478.8  143.0 
IMAC Load Flow 
Through 
5.13 41993 215.4 319.9 
Deoxycholate Wash --
†
 34860 -- 15,000
†
 
Urea Wash < 0.025 24933 -- 0.404 
IMAC High  0.81 14985 12.2 0.00049 
AXC Load Flow 
Through 
0.04 3656 0.15 0.0675 
AXC Elute 2.44 5000 ~12 0.012 
CXC Flow Through 1.89 6600 ~12 0.013 
Final Bulk Buffer 
Retentate 
7.09 1390 9.8 0.0073 
Filtered Final Bulk 
Melan-A 
4.53 1388.6 6.3 0.0096 
 
Table 1. Endotoxin and protein concentration measured during several points 
in the production process. Endotoxin limit is 1.4 EU/µg for a dose of 250 µg.  
 
† Deoxycholate wash endotoxin concentration reported as EU/ml. Protein 
concentration by Bradford was inaccurate due to high levels of Triton X-114.  
 
 160 
in the high imidazole fraction. The eluted product was concentrated to 1 L and buffer 
exchanged using tangential flow filtration (TFF) into 10 mM carbonate buffer for 
anion exchange chromatography.   
     In our previous report on the production of NY-ESO-1, we used an anion exchange 
column (AXC) as a flow though column followed by final polishing with a 
hydrophobic interaction column (HIC). During process development for Melan-A, the 
HIC column was deemed impractical for purification of Melan-A due to inefficient 
elution off of the column even with the addition of non-polar excipients. Additionally, 
detergent or alcohol removal after the HIC column is extremely difficult and results in 
a significant loss of product. Therefore, the downstream polishing column process was 
amended by converting the AXC into an elution column and replacing the HIC with a 
flow through cation exchange column.  Figure 4A shows the chromatogram of the 
AXC purification. The retentate from the post-IMAC buffer exchange was loaded onto 
the column in a 70:30 dilution ratio (V/V) with carbonate buffer. This dilution step 
allowed for increased loading capacity of the column compared to undiluted load by 
increasing flow and preventing resin fouling at the top of the column. During 
development, the retentate was also found to be slightly lower than the desired pH 
after five diafiltration volumes. Loading at a lower pH would affect column 
performance due to the protein carrying a net positive charge at a pH below the 
isoelectric point reducing binding to the strong anion exchangers in the resin. Figure 
4A-IV shows the elution of the product over six column volumes with carbonate 
buffer containing 1M NaCl. Figure 5A shows a Coomassie stained SDS-PAGE gel of 
samples from the AXC polishing step. The Melan-A monomer (14 kDa) is collected in  
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Figure 4: A) Chromatogram for anion exchange chromatography. Section I-III are 
column equilibration, load flow through and wash respectively. Section IV shows 
the elution peaks for Melan-A with 1M NaCl. B) Chromatogram for cation 
exchange chromatography. The antigen flows through the column in section II and 
the wash is completed in section III. 
A 
B 
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A 
 
 
Figure 5: A) Coomassie stained SDS-PAGE gel for anion exchange 
column. Lanes 1-8 are as follows: protein ladder, sample buffer (blank), 
blank, AXC elute, blank, AXC load flow through, blank, AXC wash. B) 
Anti-Histidine western blot for anion exchange column. Lane 
assignments are as previously stated. A large band of Melan-A monomer 
is seen at the 14 kDa band. No detectable amount of Melan-A is seen in 
the AXC load flow through or wash.    
 
B 
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the AXC elution. There was a 1% loss of total protein in the load flow through (Table 
1) and no detectable loss of total protein in the wash step. Figure 5B shows a western 
blot (Anti-His) confirming the presence of the Melan-A monomer in the elution 
fraction and the absence of product in the previous fractions.  
Figure 4B is the chromatogram for the cation exchange column (CXC). The column 
was equilibrated with two column volumes of the AXC elution buffer to ensure no 
binding to the column by the product. In this instance, the net negative charge of the 
protein and competition from other charged species would cause the product to flow 
through the cation resin. The product flow through was collected over 8 column 
volumes, which includes a 1.5 column volume washout step with AXC elution buffer. 
The CXC flow through was concentrated and buffer exchanged into the final 
formulation bulk buffer. Figure 6A and B show the Coomassie gel and western blot of 
the CXC column flow through and final bulk retentate. No product was lost in 
permeate during the final concentration step (lane 6). The product was subjected to 
dead-end sterile filtration through a 0.22 µm disk filter for final storage. Dead-end 
filtration resulted in a 35% loss in total protein (Table 1). A final summary Coomassie 
gel and western blot are shown in figure 7A & B. The IMAC provides a majority of 
the purification and endotoxin removal by including a deoxycholate wash in this step. 
The final columns serve to further reduce endotoxin levels and contaminants while 
limiting loss of product. The higher molecular weight bands that stain positive in the 
anti-histidine western blot are presumed to be Melan-A bound to chaperone proteins. 
Both DnaK and GroEL have been shown to be strongly associated with bacterial 
inclusion bodies (IB) and in the case of GroEL may play a role in the formation and  
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Figure 6: A) Coomassie stained SDS-PAGE gel for cation exchange 
chromatography and final buffer exchange. Lane assignments (1-8) are as 
follows: protein ladder, blank, blank, CXC flow through, blank, final 
concentration permeate, blank, final bulk retentate. B) Anti-Histidine western 
blot for CXC and final buffer exchange. Lane assignments are as previously 
stated.    
 
A 
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Figure 7: A) Coomassie stained SDS-PAGE gel summarizing GMP production 
of Melan-A. Lane assignments (1-10) are as follows: protein ladder, crude 
lysate, filtrate (IMAC load), IMAC low imidazole, IMAC high imidazole, post 
IMAC TFF retentate, AXC elute, CXC flow through, final bulk retentate, final 
filtered Melan-A. B) Anti-Histidine western blot of Melan-A summary gel. 
Lane assignments are as previously stated.  
 
B 
A 
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stability of IB
[27-29]
. Attempts to separate the chaperones from Melan-A proved to be 
unsuccessful despite using strong reducing agents (DTT), hydrophobic interaction 
chromatography, and varying the osmolarity of the buffer solutions (Unpublished 
Observations). The hydrophobicity of Melan-A may cause the chaperones to bind 
more tightly. A yield of 6.3 g was produced from half of the fermentation. Endotoxin 
levels in the final filtered product were less than 0.01 EU/µg. The final filtered product 
was two orders of magnitude below the LICR prescribed limit for endotoxin in a 250 
µg dose.    
 Conclusion 
GMP pilot scale production of Melan-A showed similar challenges to those seen in 
our previous report on NY-ESO-1 [8]. Melan-A is highly insoluble in aqueous 
solution and requires the presence of high concentrations of urea to stay in solution. 
Melan-A also has a strong affinity for endotoxin and like NY-ESO-1 requires a 
detergent wash step during IMAC purification to significantly reduce endotoxin levels 
before downstream purification. However, several modifications to purification 
process to tailor it to Melan-A resulted in higher yields per fermentation when 
compared to our previous work with NY-ESO-1. Additionally, endotoxin levels in the 
final bulk product were well below the specified limit for a 250 µg dose. Our final 
yield was 11.1 grams of protein from a twenty liter fermentation. This material meets 
the standards for use in phase 1 clinical trials.         
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